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Preface
The number of people with active tuberculosis in the United States steadily increased from 1985
until 1992. The population groups in the United States that are at increased risk for infection with
M. tuberculosis include the medically underserved, low-income populations, immigrants from
countries with a high prevalence of tuberculosis, and residents of long-term-care facilities. Those
at increased risk for developing disease following infection include individuals with human
immunodeficiency virus (HIV) infection; close contacts of infectious cases; children less than 5
years old; patients with renal failure, silicosis, and diabetes mellitis; and individuals receiving
treatment with immunosuppressive medications. If the diagnosis of tuberculosis is delayed,
subsequent steps to confine contagious patients are likewise delayed and nosocomial infections
may result.  
As multidrug resistant tuberculosis (MDR-TB) increasingly becomes a public health problem, the
impact on the medical community can be alarming. Investigations of four MDR-TB outbreaks in
hospitals in Florida and New York City demonstrated that most cases of MDR-TB occurred among
individuals known to be infected with HIV. The case fatality rate was high (72-89%) and the median
interval between diagnosis and death was short (4-16 weeks).
Laboratory methods to promote growth and reduce the turnaround time for reporting test results
on mycobacterial specimens are now available. It is the responsibility of the laboratory to respond
by implementing these methods. This self-assessment will provide encouragement and information
to assist you in this effort. The commitment is yours.  
Use of trade names is for identification only and does not constitute endorsement by
the Public Health Service or by the U.S. Department of Health and Human Services.
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Prevention, Public Health Practice Program Office.  This document was developed by a contractor
based on the contributions, and technical and scientific review of a panel of Mycobacteriology
experts convened by ASTPHLD and CDC.
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1INTRODUCTION
After three decades of steady decline, reported cases of TB have increased in the United States
by 20 percent, from a low of 22,201 cases in 1985 to a high of 26,673 cases in 1992. In 1993,
25,313 cases were reported, representing a 5% decline in numbers of cases.  The increases were
due primarily to five factors: 
(1) The deterioration of the public health infrastructure 
(2) Immigration of persons from countries with a high prevalence of TB
(3) Occurrence of TB in persons infected with the human immunodeficiency virus (HIV)
(4) Outbreaks and transmission of TB in congregative setting such as hospitals,
correctional, and residential care facilities 
(5) Outbreaks of multi-drug resistant TB (MDR-TB)
The control of tuberculosis requires the active support of the entire laboratory community and
coordination of the appropriate levels of service for smears, cultures, and drug susceptibility
testing.  The late diagnosis of TB and delayed recognition of drug resistance have contributed to
the dissemination of MDR-TB.  
It is imperative that we in the laboratory community prepare now to assist in detecting of
tuberculosis early by reducing the laboratory turnaround time for reporting positive smear, culture,
identification, and susceptibility results.  The laboratory has been challenged to respond in four
ways:
! Report results of acid-fast stains within 24 hours of receipt in the laboratory.
! Detect growth of mycobacteria in liquid medium within 10 days of specimen receipt.
! Identify Mycobacterium tuberculosis isolates by mycolic acid pattern, the AccuProbe
or the BACTEC NAP test within two to three weeks of specimen receipt.
! Determine the susceptibility of new M. tuberculosis isolates to primary drugs and
report results within three to four weeks of receiving the specimen.
Equipment, space, and airflow must create a safe environment within the laboratory for handling
and manipulating  infectious materials.  An immediate assessment of laboratory design, airflow,
and equipment will help you decide if changes are necessary.  If your laboratory receives fewer
than 20 mycobacteriology specimens per week, you may decide that providing a safe work
environment requires a greater investment than your institution can make.  Also, ATS recommends
a minimum of 20 mycobacteriology specimens per week to remain proficient.  It will be important
to find a good reference laboratory that can provide the needed service quickly and accurately.
Although speed is important, safety and accuracy must first be considered when implementing a
plan of action to reduce laboratory turnaround time.  Reports of laboratory cross-contamination
underscore the need for laboratories to review and adapt to methods that will minimize the
opportunity for false-positive reports. 
2This self-assessment will use the American Thoracic Society (ATS) recommendation for voluntary
classification of laboratories into Level I, II, and III(1).  This classification system was devised by
the ATS with the cooperation of the Centers Disease Control and Prevention (CDC).  A complete
description of levels is appended for your review (Appendix 1) and briefly summarized as follows:
LEVELS OF MYCOBACTERIOLOGY LABORATORY SERVICE
(AMERICAN THORACIC SOCIETY)
Level I Laboratory: Collect good specimens; ship to Level II or III Laboratory for culture
(CAP/HCFA Level 1&2) and susceptibility tests.  
May prepare and examine smears for presumptive diagnosis of
tuberculosis or for patient follow-up.  Participate in proficiency testing
program for acid-fast smears, if  applicable.
(NOTE:  This self-assessment instrument only applies to Level I
laboratories that prepare and examine AFB smears.  This self-
assessment is not designed for laboratories, facilities, or clinics
that only collect and transport specimens.)
Level II Laboratory: Perform all procedures  performed  by Level  I  Laboratory.   Perform
(CAP/HCFA Level 2&3) microscopic examination.  Isolate organisms in pure culture.  Identify
Mycobacterium tuberculosis complex.  Perform susceptibility tests on
M. tuberculosis complex*.  Refer mycobacterial isolates other than M.
tuberculosis to Level III Laboratory for identification and susceptibility
testing.
 
Proficiency testing for a Level II Laboratory should include acid-fast
smears, isolation of mycobacteria, identification of M. tuberculosis
complex, and susceptibility of M. tuberculosis complex.
Level III Laboratory: Perform all procedures of Level I and II Laboratories.  Identify all
(CAP/HCFA Level 4&5) mycobacteria.  Perform susceptibility tests* on other mycobacteria.
Proficiency testing for a Level III Laboratory should include acid-fast
smears, isolation of mycobacteria, and identification and susceptibility
testing of other mycobacteria.
* Laboratory personnel should not perform susceptibility tests unless they:
(a) can identify the organism they are testing and
(b) perform a sufficient number of susceptibility tests to be aware of the many problems
associated with the procedure.
3This assessment will provide you the information, encouragement and opportunity to
thoroughly review your procedures, assign priorities, and adopt a plan to update your
laboratory practices if needed. Use the questionnaire to identify areas that can make a
difference in your mycobacteriology program.  Decide what prevents you from creating an
environment for change.  Whether it be equipment, personnel, or space, no change can
occur until you have a plan.  Create a mood and a climate for introducing newer methods
and newer techniques; then work to make it happen.  YOU CAN MAKE THE DIFFERENCE
AND YOU CAN EFFECT CHANGE!
4
5SCORING THE SELF-EVALUATION QUESTIONS
1. The questions have been rated taking the following criteria into account:
# Safety
# Good Laboratory Practices
# CDC guidelines and initiatives (Appendix 5)
# A ranking provided by a committee of experts in the field (see Technical Advisory
Committee listing in introductory pages)
2. Allow several people in your organization to participate in the self-assessment process.
Score sheets may be copied as necessary.  Separate scoring sheets have been developed
for the Level I (pp. 9-12), Level II (pp. 13-20), and Level III (pp. 21-27) laboratories.
3. Answer questions defined by your level of service, at the level you are working.  You may
be exceeding the ordinary Level I practice by adding tests ordinarily rated for Level II
laboratories.
(Note: This self-assessment instrument is designed for laboratories that prepare and
examine AFB smears, not laboratories or facilities that only collect and transport
specimens.)
Level I laboratories that prepare smears and perform AFB microscopy should only answer
questions 1-41.
4. All questions can be answered with a yes or no response.
a. If the answer is yes, record the maximum point value (in column labeled "VALUE")
in the "SCORE" column. 
EXAMPLE: The answer to question #1 is affirmative--record a point value of "3" in
the "SCORE" column. 
QUEST VALUE SCORE COL/ SAFETY LAB QA/QC CDC
HAND PRAC RECOM
1 3 3
b. If the answer is no record a "0" in the "SCORE" column.
EXAMPLE: The answer to question #2 is negative--record a point value of "0" in the
"SCORE" column.
QUEST VALUE SCORE COL/ SAFETY LAB QA/QC CDC
HAND PRAC RECOM
1 3 3
2 3 0
6c. On those questions with multiple parts, answer yes only if you can answer yes to all
portions of the question.
d. Score each question accurately; the score is important only as an indicator of need
for improvement or as a mandate for change.
5. You will note other columns on your score sheet--these are labeled as follows:
# Col/Hand Specimen Collection & Handling
# Safety Safety
# Lab Prac Laboratory Practice
# QA/QC Quality Assurance & Quality Control
# CDC Recom CDC Recommendations
Sorting your score into these categories will enable you to define your laboratory's area(s)
of strength or weakness.
6. In addition to recording the score for each question in the "SCORE" column, also record it
in the unshaded column(s).  There may be one or more columns appropriate for each
question.
EXAMPLE: The answer to #1 is affirmative:  score 3 in the "SCORE" column; also score
3 in "COL/HAND" column.  If the answer to #2 is negative, score "0" in the "SCORE" and
"COL/HAND" columns.
QUEST VALUE SCORE COL/ SAFETY LAB QA/QC CDC
HAND PRAC RECOM
1 3 3 3
2 3 0 0
7. When all questions are scored, subtotal the score as appropriate for the given levels, i.e.
for a Level I, Level II, or Level III laboratory.  Also add each of the categorical columns and
convert to a percent score by dividing your score by the total value of questions answered
for that category.  
8. For laboratories answering questions exclusively assigned to their level, the following total
values will be useful for determining the percent scores:
Level I Laboratory: Total VALUE points = 197
Level II Laboratory: Total VALUE points = 414
Level III Laboratory: Total VALUE points = 432
Adjust your total VALUE (denominator) based on the additional questions answered in the
survey.
7Example:  Your Laboratory exceeds the basic Level I Laboratory activity by inoculating
cultures, but refers growth.  This activity will require that you answer all questions on
concentration, safety, and culture examination, including QC and QA.  Answer those
questions, and include the total in your VALUE (denominator) and SCORE (numerator)
totals.
 9. To determine your percent score, divide the SCORE by the VALUE.
Total of Affirmative responses (SCORE Column)
__________________________________________________________
Total of Affirmative and Negative Responses (VALUE Column)
The same method should be used to determine the percentage score in the categories listed
in columns 4-8.  Use the total values listed on chart for your Level (I-III) of service as the
denominator and your total value of affirmative responses as the numerator.
10. Convert the scores to percent by dividing your score in each column by the total number of
points possible for that column.
8INTERPRETING YOUR SCORE
1. After the key players in your organization have had an opportunity to score the self-
assessment, meet to compare and analyze the results.
2. Objectively evaluate the results.  This self-assessment will not be useful unless you act
upon identified needs.
3. Reference scores of laboratories that are deemed to be performing at an "excellent" level
are given in the appendix:  Reference Scores, Appendix 11.  Use these scores to assess
where your laboratory stands in comparison with other organizations.
4. The questions marked with an * and appear in red throughout the self assessment are
"key questions."  These are considered of such significance that a negative answer
to them should be a flag to evaluate whether or not your laboratory should be offering
testing for mycobacteria.  If your answer to any one of these 10 questions is "no", you
should immediately take steps to implement change, or begin referring your
mycobacteriology specimens to a full-service laboratory in your area.
5. Develop a plan of action that includes the newer, rapid methods to facilitate early
recognition of M. tuberculosis.  Consult with the medical staff, the local or state health
department, and the local or state TB control office.  The Guidelines have been developed
to provide advice as you formulate a plan.  
6. Follow the plan--the results can be dramatic (see Appendix 2:  "Success Story: New York
State Laboratory").
7. We suggest that you repeat the self assessment periodically to track your progress.
REMEMBER THAT ANY PLAN BEGINS WITH YOU AND YOUR
LABORATORY!  WITH YOUR ACTION MAYBE WE CAN STILL ELIMINATE
TB IN THE UNITED STATES BY THE YEAR 2010!
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N O T E S
*Signifies Key question 9
MYCOBACTERIUM TUBERCULOSIS SELF-ASSESSMENT SURVEY
SCORE SHEET FOR LEVEL I LABORATORIES
(ANSWER QUESTIONS 1 - 41)
Affirmative Response: Enter question VALUE in SCORE column and in unshaded
category column.
Negative Response: Enter "0"  in SCORE column and in unshaded category column.
QUEST VALUE SCORE COL/ SAFETY LAB QA/QC CDC  
HAND PRAC RECOM
1 3
2 3
3 3
4 2
5 2
6 2
7 6
8 3
9 6
10 3
11 3
12 2
13 6
14 4
15 3
16 3
17 3
18 4
19 4
20 4
21 8
*22 9
Page
Scores
MYCOBACTERIUM TUBERCULOSIS SELF ASSESSMENT/LEVEL I
QUEST VALUE SCORE COL/ SAFETY LAB QA/QC CDC  
HAND PRAC RECOM
*Signifies Key question 11
Previous
page
scores
23 8
24 3
25 3
26 6
27 6
28 3
*29 8
30 7
31 5
32 8
33 7
*34 8
35 3
36 8
37 8
38 6
39 3
40 3
*41 8
Your
Total
Scores
Possible 197 63 59 98 63 123
Scores
To determine your percent score, divide your total score by the possible score.
If your laboratory exceeds the basic Level I laboratory activity, but is not a true Level II laboratory,
you can correct for this by answering the questions in Level II that apply to your operations and
adjusting the possible score (denominator) based on the additional questions answered in the
survey.
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The same method can be used to determine the percent score in the categories listed in columns
4-8.  Use the possible score listed on chart as the denominator and your total score as the
numerator.
Percent scores may be compared with the reference scores from "excellent" laboratories located
in Appendix 12.
Work Space
Your Total Score                    ÷   Possible Score              x   100   =           %
Your Col/Hand Score                   ÷   Possible Col/Hand Score              x   100   =           %
Your Safety Score                   ÷   Possible Safety Score              x   100   =           %
Your Lab Prac Score                   ÷   Possible Lab Prac Score              x   100   =           %
Your QC/QA Score                   ÷   Possible QC/QA Score              x   100   =           %
Your CDC Recom Score               ÷   Possible CDC Recom Score             x   100   =           %
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N O T E S
*Signifies Key Question 13
MYCOBACTERIUM TUBERCULOSIS SELF-ASSESSMENT SURVEY
SCORE SHEET FOR LEVEL II LABORATORIES
(ANSWER QUESTIONS 1-39; 42-80)
Affirmative Response: Enter question VALUE in SCORE column and in unshaded category
column.
Negative Response:     Enter "0"  in SCORE column and in unshaded category column.
QUEST VALUE SCORE COL/ SAFETY  LAB QA/QC CDC  
HAND PRAC RECOM
1 3
2 3
3 3
4 2
5 2
6 2
7 6
8 3
9 6
10 3
11 3
12 2
13 6
14 4
15 3
16 3
17 3
18 4
19 4
20 4
21 8
*22 9
Page
Scores
MYCOBACTERIUM TUBERCULOSIS SELF ASSESSMENT/LEVEL II
QUEST VALUE SCORE COL/ SAFETY  LAB QA/QC CDC  
HAND PRAC RECOM
*Signifies Key Question 15
Previous
Page
Scores
23 8
24 3
25 3
26 6
27 6
28 3
*29 8
30 7
31 5
32 8
33 7
*34 8
35 3
36 8
37 8
38 6
39 3
*42 8
43 9
44 4
45 6
46 5
47 5
48 4
49 3
*50 9
Page
Scores
MYCOBACTERIUM TUBERCULOSIS SELF ASSESSMENT/LEVEL II
QUEST VALUE SCORE COL/ SAFETY  LAB QA/QC CDC  
HAND PRAC RECOM
*Signifies Key Question 17
Previous
Page
Scores
51 4
52 4
*53 8
54 7
55 8
56 3
57 7
58 3
59 8
60 6
61 4
62 8
63 8
*64 8
65 8
*66 8
67 5
68 2
69 4
70 2
71 5
72 2
73 8
74 8
75 8
*76 8
Page
Scores
QUEST VALUE SCORE COL/ SAFETY  LAB QA/QC CDC  
HAND PRAC RECOM
19
Previous
Page
Scores
77 8
78 5
79 5
80 3
Your
Total
Scores
Possible 414 60 93 269 115 290
Scores
To determine your overall (column 2) percent score, divide your total score (column 3) by the
possible score.
The same method can be used to determine the percent score in the categories listed in columns 4-8.
Use the possible score listed on chart as the denominator and your total score as the numerator.
Percent scores may be compared with the reference scores from "excellent" laboratories located in
Appendix 12.
Work Space
Your Total Score                    ÷   Possible Score              x   100   =           %
Your Col/Hand Score                   ÷   Possible Col/Hand Score              x   100   =           %
Your Safety Score                   ÷   Possible Safety Score              x   100   =           %
Your Lab Prac Score                   ÷   Possible Lab Prac Score              x   100   =           %
Your QC/QA Score                   ÷   Possible QC/QA Score              x   100   =           %
Your CDC Recom Score               ÷   Possible CDC Recom Score            x   100   =           %
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N O T E S
16
N O T E S
18
N O T E S
20
N O T E S
*Signifies Key Question 21
MYCOBACTERIUM TUBERCULOSIS SELF-ASSESSMENT SURVEY
SCORE SHEET FOR LEVEL III LABORATORIES
(ANSWER QUESTIONS 1-39; 42-84)
Affirmative Response: Enter question VALUE in SCORE column and in unshaded category
column.
Negative Response:     Enter "0"  in SCORE column and in unshaded category column.
QUEST VALUE SCORE COL/ SAFETY LAB QA/QC CDC  
HAND PRAC RECOM
1 3
2 3
3 3
4 2
5 2
6 2
7 6
8 3
9 6
10 3
11 3
12 2
13 6
14 4
15 3
16 3
17 3
18 4
19 4
20 4
21 8
*22 9
Page
Scores
MYCOBACTERIM TUBERCULOSIS SELF ASSESSMENT/LEVEL III
QUEST VALUE SCORE COL/ SAFETY LAB QA/QC CDC  
HAND PRAC RECOM
*Signifies Key Question 23
Previous
Page
Scores
23 8
24 3
25 3
26 6
27 6
28 3
*29 8
30 7
31 5
32 8
33 7
*34 8
35 3
36 8
37 8
38 6
39 3
*42 8
43 9
44 4
45 6
46 5
47 5
48 4
49 3
*50 9
Page
Scores
MYCOBACTERIM TUBERCULOSIS SELF ASSESSMENT/LEVEL III
QUEST VALUE SCORE COL/ SAFETY LAB QA/QC CDC  
HAND PRAC RECOM
*Signifies Key Question 25
Previous
Page
Scores
51 4
52 4
*53 8
54 7
55 8
56 3
57 7
58 3
59 8
60 6
61 4
62 8
63 8
*64 8
65 8
*66 8
67 5
68 2
69 4
70 2
71 5
72 2
73 8
74 8
75 8
*76 8
Page
Scores
QUEST VALUE SCORE COL/ SAFETY LAB QA/QC CDC  
HAND PRAC RECOM
27
Previous
Page
Scores
77 8
78 5
79 5
80 3
81 5
82 4
83 7
84 2
Your Scores
Possible 432 60 93 285 117 297
Scores
To determine your overall (column 2) percent score, divide your total score (column 3) by the
possible score.
The same method can be used to determine the percent score in the categories listed in columns 4-8.
Use the possible score listed on chart as the denominator and your total score as the numerator.
Percent scores may be compared with the reference scores from "excellent" laboratories located in
Appendix 12.
Work Space
Your Total Score                    ÷   Possible Score              x   100   =           %
Your Col/Hand Score                   ÷   Possible Col/Hand Score              x   100   =           %
Your Safety Score                   ÷   Possible Safety Score              x   100   =           %
Your Lab Prac Score                   ÷   Possible Lab Prac Score              x   100   =           %
Your QC/QA Score                   ÷   Possible QC/QA Score              x   100   =           %
Your CDC Recom Score               ÷   Possible CDC Recom Score             x   100   =           %
N O T E S
22
26
N O T E S
24
N O T E S
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MYCOBACTERIUM TUBERCULOSIS: ASSESSING YOUR LABORATORY
PART I: SELF ASSESSMENT QUESTIONS
ALL LABORATORIES ANSWER QUESTIONS 1-39
SPECIMEN COLLECTION AND HANDLING
Does your Mycobacteriology Laboratory:
 1. Provide written instructions that are easily understood by the person collecting the
patient specimen? 
 2. Include instructions to the providers for:
a. The submission form and its use?
b.  Specimen labeling?
c. The volume of specimen required?
d. Packaging the specimen for delivery or transport?
 3. Obtain the following information when not included on the submission form:
a. Patient's name?
b. Physician's name, address, telephone number?
c. Test(s) to be performed?
d. Date and time of collection?
e. Pertinent specimen information?
 4. Provide transport containers and specimen submission forms to health care
providers upon request?
 5. Supply new, sterile, 50ml plastic conical centrifuge tubes with screw-cap closures for
collecting respiratory specimens?
 6. Monitor the number of specimens collected per patient (3-6) as part of the quality
assurance program?
 7. Monitor the delivery time to assure that less than 24 hours have elapsed between
specimen collection and its arrival at the laboratory?
 8. Communicate regularly with providers to promote understanding and cooperation?
 9. Verify that the patient's name and/or identification number on each specimen
container matches that on the submission form?
30
10. Furnish the health care provider with a copy of the laboratory's:
a. Criteria for rejecting specimens?
b. Reporting policy?
11. Include the following information on the specimen report form:
a. Name and address of your laboratory?
b. Date and time the specimen was received in your laboratory?
c. Name and address of testing laboratory, if different from "a?"
d. Test results?
e. Drug susceptibility results, when performed?
12. Record the number of specimens rejected and the reason for rejection as part of the
quality assurance program?
13. Report unsatisfactory specimens to the provider within 24 hours of receipt?
SAFETY
Does your Mycobacteriology Laboratory:
14. Follow a written biosafety plan that:
a. Defines safe laboratory practice?
b. Includes procedures for handling spills and other emergencies?
15. Require employees to review the biosafety plan annually?
16. Follow a written chemical hygiene plan that defines safe laboratory practice?
17. Evaluate the risk associated with the procedures performed in your laboratory?
18. Monitor the Mantoux tuberculin skin test (TST) conversion rate of your personnel as
a part of a risk assessment plan?
19. Provide for new employees:
a. A two step Mantoux tuberculin skin test (TST)?
b. A medical evaluation, including a chest radiograph, if TST is positive?
20. Provide for all employees:
a. An annual Mantoux test on TST negative employees?
* Key question: A negative response to any key question should cause you to
reconsider whether your laboratory should offer TB testing!
31
b. A chest radiograph and medical evaluation if the skin test converts to positive
or symptoms of tuberculosis are exhibited?
c. Medical evaluation, counseling, and follow-up for any known exposure event
or TST conversion?
d. A permanent record of skin testing results?
21. Provide safety training on aerosol prevention techniques for all employees before
assigning work with TB specimens or cultures?
*22. Use a  Class I, II, or III biological safety cabinet (BSC) that has been certified annually?
23. Perform all manipulations on mycobacterial specimens and cultures that may
generate  aerosols only in a BSC?
24. Provide personal protection equipment that includes laboratory coats or gowns,
gloves, and face protection?
25. Decontaminate all personal protection equipment before it leaves the laboratory area?
LABORATORY PRACTICE
Does your Mycobacteriology Laboratory:
26. Participate in an approved proficiency testing program?
27. Follow standard operating procedures and maintain the results of quality control for
each test procedure for two years?
28. Label all reagents to indicate identity, strength or concentration, storage
requirements, preparation and expiration dates?
*29. Prepare and examine >10 acid-fast smears per week?  
30. Use the fluorochrome stain as the primary acid-fast stain for smears made from the
patient's specimen?
31. Check positive and negative reactivity of fluorochrome acid-fast stain each day of use
by staining and examining known acid-fast and non-acid-fast organisms?
32. Examine acid-fast smears the day they are stained?
33. Report an approximation of the number of acid-fast organisms viewed on the slide?
* Key question: A negative response to any key question should cause you to
reconsider whether your laboratory should offer TB testing!
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*34. Telephone, fax, or electronically report all positive acid-fast smear results to the
health care provider as soon as results are known, but within 24 hours from specimen
receipt?
35. Record the date and time positive smear results were telephoned, faxed, or
electronically reported to the health care provider?
36. Telephone, fax or electronically report all positive acid-fast smear results to the
public health department no longer than 24 hours from specimen receipt and follow
with a written report?
37. Deliver or mail a written microscopy report to the health care provider within 48 hours
of specimen receipt in the laboratory?
38. Maintain all patient reports and test records for two years?
39. Assure confidentiality of all patient information?
ONLY LEVEL I LABORATORIES ANSWER QUESTIONS 40 & 41
Does your Mycobacteriology Laboratory:
40. Limit access into the laboratory when specimens are being processed?
*41. Send all specimens to a full service laboratory for culture within 24 hours of receipt?
LEVEL II AND III LABORATORIES ANSWER QUESTIONS 1-39; 42-80
Does your Mycobacteriology Laboratory:
*42. Process and culture >20 specimens per week?
43. Take steps to eliminate cross-contamination between cultures?
44. Routinely process and culture specimens seven days a week?
45. Use a refrigerated centrifuge(s) at a relative centrifugal force (RCF) of  at  least 3000
for 15 minutes to process mycobacterial specimens for culture?
46. Use only safety carriers equipped with O-ring closures when centrifuging specimens?
* Key question: A negative response to any key question should cause you to
reconsider whether your laboratory should offer TB testing!
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47. Prepare, stain, and examine acid-fast smears from all specimens sent to the
laboratory for mycobacterial culture?
48. Have an isolation room for mycobacteriology that is separate from the rest of the
laboratory?
49. Keep laboratory doors closed when mycobacterial specimens are being processed?
*50. Have a one-pass (non-recirculating) ventilation system that establishes an airflow
pattern, moving from clean (e.g., corridor) to least clean area (e.g., the isolation
laboratory)?
51. Monitor the environmental conditions in the isolation room annually to determine the
number of air exchanges and the negative pressure status?
52. Control access to the laboratory when working with mycobacterial specimens?
*53. Inoculate all digested/decontaminated, concentrated sediments into a selective broth,
e.g., the BACTEC System, for the primary culture?
54. Inoculate all specimens not requiring decontamination into a broth, e.g., the BACTEC
System, for the primary culture?
55. Inoculate digested/decontaminated, concentrated sediments of mycobacterial
specimens to at least one solid medium?
56. Inoculate a negative control each day cultures are inoculated?
57. Perform direct drug susceptibility testing with the primary drugs using the
concentrated sediment of smear positive specimens?
58. Inoculate a control with a strain of M. tuberculosis susceptible to all
antimycobacterial agents being tested, each time a drug susceptibility test is
performed?
59. Examine broth cultures for evidence of growth every 2-3 days for weeks 1-3, and
weekly thereafter for a total of 6 weeks?
60. Examine cultures on solid media for evidence of growth twice weekly for 1-4 weeks,
and weekly thereafter for a total of 8 weeks?
61. Use a microscope or hand lens to examine agar plates and/or tubes for earlier
visualization of mycobacterial growth?
* Key question: A negative response to any key question should cause you to
reconsider whether your laboratory should offer TB testing!
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62. Perform an acid-fast smear from:
a. BACTEC vials exhibiting growth?
b. Selected colonies at an early stage of growth on solid medium?
63. Subculture all BACTEC vials exhibiting acid-fast growth to solid medium?
*64. Use a rapid method to presumptively or specifically confirm the presence of M.
tuberculosis complex:
a. From BACTEC vials?
b. From growth on solid media?
65. Telephone, fax, or electronically transmit a confirmed report of M. tuberculosis
complex to provider as soon as the results are available and follow with a written
report within 24 hours?
*66. Average 14-21 days between receiving specimen and reporting M. tuberculosis
complex on positive specimens?
67. Monitor the turnaround time of test results to ensure that the majority of M.
tuberculosis complex are identified within 21 days of specimen receipt?
68. Retain positive mycobacterial cultures for 1 year?
69. Correlate the smear positive and negative results with culture positive and negative
results to evaluate the smear/culture quality?
70. Document the percent of specimens producing contaminating growth on culture
media inoculated with digested/decontaminated sediment as a way of monitoring the
specimen preparation process?
71. Subculture colonies with differing morphology for use in species identification?
72. Compare the prevalence of M. tuberculosis complex isolated in your laboratory to the
prevalence in your geographic area?
73. Perform susceptibility tests on all initial isolates of M. tuberculosis?
74. Determine the susceptibility of M. tuberculosis complex to primary drugs using a
liquid system such as BACTEC?
* Key question: A negative response to any key question should cause you to
reconsider whether your laboratory should offer TB testing!
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75. Telephone, fax, or electronically transmit a drug susceptibility report to provider as
soon as results are available and follow with a written report within 24 hours?
*76. Average 15-30 days between receiving specimen and reporting primary drug
susceptibility test results on M. tuberculosis complex?
77. Telephone, fax, or electronically report results of confirmed M. tuberculosis complex
and resistant strains of M. tuberculosis to the Tuberculosis Control Program in the
state where the patient resides, as soon as the results are available?
78. Monitor the turnaround time for reporting primary drug susceptibility test results on
M. tuberculosis isolates to ensure that reports are sent within 30 days of specimen
receipt?
79. Monitor the resistance patterns of M. tuberculosis and make information available to
house staff, local and state Tuberculosis Control Program?
80. Submit outbreak-associated strains of M. tuberculosis through the state laboratory
to a restriction fragment length polymorphism (RFLP) reference laboratory for
fingerprinting?
LEVEL III LABORATORIES ANSWER QUESTIONS 1-39; 42-84
Does your Mycobacteriology Laboratory:
81. Identify a broad range of Mycobacterium species?
82. Perform drug susceptibility studies against other mycobacteria in addition to M.
tuberculosis?
83. Use one of the following rapid methods to identify mycobacteria:
a. DNA probe?
b. High performance liquid chromatography (HPLC)?
84. Not report the identification of M. tuberculosis based solely on polymerase chain
reaction (PCR) results?
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MYCOBACTERIUM TUBERCULOSIS: ASSESSING YOUR LABORATORY
PART II: GUIDELINES
SPECIMEN COLLECTION AND HANDLING
Regulations implementing the Clinical Laboratory Improvement Amendments of 1988 (CLIA) specifically
addresses the laboratory responsibility in the area of patient test management (19). (Appendix 3, Interpretive
Guidelines).
Patient Test Management For Moderate or High Complexity Testing: The laboratory must employ and
maintain a system that provides for proper patient preparation; proper specimen collection, identification,
preservation, transportation and processing; and accurate result reporting. The laboratory system must assure
optimum patient specimen integrity and positive identification throughout the pretesting, testing, and post-
testing processes.
The efficacy of the laboratory smear examination, culture procedures and susceptibility testing from clinical
specimens depends upon the collection and transport of quality specimens. A poor specimen collected and
transported haphazardly will probably yield useless or misleading results. Specimens should be collected in
sterile containers and transported without delay. The laboratory staff can provide information that will promote
high quality specimens.
Procedures for Specimen Submission and Handling
The laboratory must have available and follow written policies and procedures for:
! Education of the patient to properly produce specimens
! Specimen collection
! Specimen labeling
! Specimen preservation, when appropriate (i.e., urine or gastric specimens)
! Specimen processing
! Specimen transport
These policies and procedures must assure positive identification and optimal integrity
of the specimen from collection to reporting.
For Referral Specimens:  A laboratory must refer specimens for testing only to a
laboratory possessing a valid certificate authorizing the performance of testing in the
specialty or subspecialty of service for the level of complexity in which the referred test
is categorized.
The referring laboratory must not revise results or information directly related to the
interpretation of results provided by the testing laboratory.
The referring laboratory must retain or be able to produce an exact duplicate of the
testing laboratory report.
The authorized person who orders a test or procedure must be notified by the referring
laboratory of the name and address of each laboratory location at which a test was
performed.
The laboratory
must follow a
written procedure
for specimen 
submission and
handling.
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The accuracy of a
laboratory test
results can be
directly related to specimen. Information should be provided to the patient on the volume of specimen
the quality of the
specimen
collected and
delivered to the
laboratory.
ALL LABORATORIES ANSWER QUESTIONS 1-39
1. Does your Mycobacteriology Laboratory provide written instructions that are
easily understood by the person collecting the patient specimen? 
The health care professional responsible for collecting mycobacteriology specimens
should be informed by the laboratory of the necessity for utmost care in collection
and handling the specimens.  The results of tests, as they affect patient diagnosis
and care, can be directly related to the quality of specimen collected and delivered
to the laboratory.  It is advisable for the laboratory to develop a working relationship
with the health care professionals who collect the specimens for mycobacteriology
so that information can be freely exchanged.
Patients should be instructed by the attending medical personnel in methods and
importance of proper specimen production and collection.
Specific instruction to patients should include information on the difference between
sputum and saliva or nasopharyngeal secretions, the necessity for a deep,
productive cough, and rinsing the mouth with water before collecting a sputum
needed and on ways to minimize contamination of early morning, mid-stream urine
specimens.
The patient should be informed of the possibly infectious nature of his or her
secretions, and the need to tightly close the collection container after the specimen
is collected.  The specimen should not contaminate the outside of the tube or
collection container.
Collection:  The specimen is preferably collected under the direction of a trained
health care professional. Because of the infectious nature of tuberculosis and the
danger to the health care professional, guidelines have been developed that
specifically address the necessity for control of conditions under which specimens
are collected.
Written laboratory instruction to providers should include the following:
! Collect a series of three to six single, early morning deep cough sputum
specimens on consecutive days.  If two of  the first three sputum smears are
positive, three specimens are enough to confirm the diagnosis.  If none or only
one of the first three sputum smears is positive, then additional (usually three)
specimens are  needed for culture confirmation of disease.  A few patients shed
mycobacteria in small numbers and only irregularly; for these patients, the
greater the number of specimens cultured, the greater the likelihood of
obtaining a positive culture.
! Collect specimens before chemotherapy is started; even a few days of drug
therapy may kill or inhibit sufficient numbers of mycobacteria to prevent
isolation.
! Multiple specimens collected on the same patient on the same day do not
represent separate specimens.
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The efficacy of the laboratory procedure used to culture mycobacteria from clinical
specimens depends on the manner in which the specimen is obtained and handled.
Therefore, following collection, specimens should be transported as quickly as
possible to the laboratory, preferably within 30 minutes. Specimens delayed longer
than 30 minutes before transport should be refrigerated.
Other lung secretion specimens include induced sputum, gastric lavage, bronchial
washings, and laryngeal exudates.  Non-sputum specimens include urine, body
fluids, tissue, and wound swabs.  Each type specimen requires special handling and
transport.
2. Does your Mycobacteriology Laboratory include instructions to the providers
for:
a. The submission form and its use?
b. Specimen labeling?
c. The volume of specimen required?
d. Packaging the specimen for delivery or transport?
2a. Instruction to the provider should encourage completing the specimen submission
form as a part of the institutional or hospital information system. The provider should
be encouraged to separate the specimen from the form during shipment by placing
it between the outer and inner container, or in a pocket provided for the specimen
form. CLIA regulation 493.1105 requires that the specimen form include the following
information:
! Patient name or other unique identifier
! Name and address or suitable identifiers of an authorized person requesting
test and, if appropriate, the person using the test results
! Test(s) to be performed
! Date of specimen collection
This information must become a part of the patient's record and be retained for at
least two years.  Other information that is of value includes:
! Hospital or clinic number
! Social security or Medicaid/Medicare number
! Patient's age or birth date
! Record of antituberculosis drugs
! Specimen number in series of samples on a single individual
! Specimen type
! Time of collection
! Relevant clinical history
! Name of contact person to notify if the results are positive
! If the specimen is received from another laboratory
It is important to seek the assistance of the state Tuberculosis Control Officer and
infectious disease physician when designing a new form.
The laboratory must perform tests only upon written or electronic request of an
authorized person; oral requests are permitted only if the laboratory subsequently
obtains written authorization for testing within 30 days.  Attempts to obtain written
authorization must be documented.
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The transport
system must:
!Protect the staff
and environment
from possible
exposure in case
of leakage.
!  Separate the
form from the
specimen.
! Ensure the
safety of anyone
handling the
specimen during
transport.
2b. Does your Mycobacteriology Laboratory include instructions to provider for
specimen labeling?
The labeling must assure positive identification and optimum integrity of the patient
specimen from collection to reporting.  Laboratory written policy, in keeping with the
above CLIA regulation, can define an acceptable labeling requirement and should
be included in provider instructions.  Providers should be expected to comply with
this reasonable request, and any deviation from the laboratory requirement for
proper labeling is reason to reject the specimen. 
2c. Does your Mycobacteriology Laboratory include instructions to the provider for
the volume of specimen required?
Provider instructions should include a request for individual sputum volume of not
less than 5ml, nor more than 10ml. This specimen volume provides adequate space
in the 50ml conical centrifuge tube for adding the decontaminant, diluent, and
subsequently centrifuging without compromising the quality of the specimen. Less
than 5ml does not provide the optimal opportunity for recovery of mycobacteria;
however, the decision to refuse to process a sample <5ml in volume is controversial.
Low quality or inadequate quantity of sputum specimen should be called to the
attention of attending medical personnel. The microbiologist should be prepared to
process any intact specimen received. The requirement for submitting acceptable
volumes of different specimens should be included in the client/physician
instructions.
2d. Does your Mycobacteriology Laboratory include instructions to the provider for
packaging the specimen for delivery or transport?
In-house specimens should be collected in appropriate tubes (50ml plastic screw-
capped centrifuge tubes), and delivered in transport containers that:
! protect the staff and environment from possible exposure in case of leakage.
! separate the form from the specimen.
! ensure the safety of anyone handling the specimen during transport.
Specimen forms are handled by staff who are not protected by personal protection
equipment.  It is very important to keep the form separated from the specimen itself,
keep it uncontaminated for the safe handling by personnel not wearing protective
gear. Any form that may have been contaminated by the specimen should be
sterilized by autoclaving.
Federal Postal Regulations must be met  when using the postal service to send
samples containing etiologic agents.  The same safety precautions should apply
when samples are being transported by any other third party carriers (Appendix 4).
Double transport cartridges suitable for specimen transport by a third party carrier
or by the U.S. Postal Service are available. These containers are rugged, reusable,
and designed for safety. Proper packaging reduces the number of broken
specimens, contains and absorbs leaking specimens,  and helps ensure the safety
of personnel handling them.
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3. Does your Mycobacteriology Laboratory obtain the following information when
not included on the submission form:
a. Patient's name?
b. Physician's name, address, telephone number?
c. Test(s) to be performed?
d. Date of collection?
e. Pertinent specimen information?
The information listed is required by CLIA.  This information must be present or must
be solicited when not included.  Obtain information that is essential to the provision
of accurate results before reporting.  QA guidelines require that you monitor your
program regularly to ensure the availability of this information on  each specimen
submitted.
The information required by your individual laboratory may be more extensive, and
with good reason.  However, if you are requesting information that is not necessary
or is not usually supplied, it may be time to review your submission form.  As a way
to monitor the relevance and necessity of requested information, compare the
information sought and the information received on a sample number of specimen
forms. Documentation provides a record of the monitoring activity.
Scheduled quality assurance documentation should include an ongoing means to
assess the quality of the information received by the laboratory. An example of an
indicator plan would be to "review 10% of the specimen forms every other week for
completeness." You could develop a simple form to record the observations and
record ongoing results in the QA manual. With an indication of poor compliance from
any one or several providers, you could initiate a plan of action.  
If your monitoring system indicates a non-compliance problem, examine your
specimen form to determine the value of the information requested:
! Is this information necessary?
! How is the information used?
! What would be the consequences of deletion?
! Can the information requested reasonably be supplied?
! What information is needed by the TB Control Program?
After evaluating each field of the specimen information form, it may be possible to
reduce or eliminate the request for information of little consequence to the laboratory
or the medical staff. This action will be recognized by the clinic or hospital as an
effort by the laboratory to reduce unnecessary record keeping.  It also helps the
laboratory by reducing the number of fields that must be recorded.
CLIA does not detail specific QA monitors nor the remedial action.  Any plan adopted
by your organization, however, should be appropriate to define and resolve patient
test management problems.
CLIA regulations
require that
certain
information is
included on
specimen form:
a. Patient's name.
b. Physician's
name (or other
authorized
person's),
address,
telephone
number.
c. Test to be
performed.
d. Date of
collection.
3. Pertinent
specimen
information.
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4. Does your Mycobacteriology Laboratory provide transport containers and
specimen submission forms to health care providers upon request?
Although no regulation specifically addresses the necessity for providing transport
material to providers, so doing helps control the quality of the specimen. The
containers for submission should be appropriate for the transport system in place.
Laboratory designed and distributed specimen submission forms specific for the
mycobacteriology program ensure the accessibility of the information necessary for
proper testing, reporting and follow-up.
5. Does your Mycobacteriology Laboratory supply new, sterile, 50ml plastic
conical centrifuge tubes with screw-cap closures for collecting respiratory
specimens?
The vial or tube for collecting a mycobacteriology specimen must be sterile and
leakproof.  Preferably all respiratory specimens are  collected in 50ml centrifuge
tubes for ease of handling, consistency, and safety.  These tubes are designed with
screw caps for watertight closure.  Urine cups are not suitable for collecting TB
specimens.
50ml plastic, disposable centrifuge tubes are recommended; they are optimal for
collection and processing specimens for these reasons:
! Eliminate an opportunity for mislabeling.
! Allow space for adequate mixing of the specimen and the digesting agent.
! Allow the specimen to be diluted in the specimen container.
! Can be centrifuged without transfer or aerosol formation.
All centrifugation should be performed using safety cups to enclose the  centrifuge
tubes.  Overfilled tubes may result in leakage during the centrifugation. 
6. Does your Mycobacteriology Laboratory monitor the number of specimens
collected per patient (3-6) as part of the quality assurance program?
Monitoring the number and succession of specimens on each patient identifies
collection problems that otherwise might go unnoticed. Since some patients shed
mycobacteria intermittently and only in small numbers, collecting a greater number
of specimens increases the likelihood of obtaining a positive culture.  The number
of bacilli in a specimen varies from patient to patient and from day to day.  Since
guidelines recommend the collection of three to six specimens per patient,
monitoring the number of specimens submitted per patient will improve the quality
of the laboratory program and increase the interaction between hospital and
laboratory staff.
Specific monitoring activity can be based on reviewing a certain number or
percentage of specimens by patient per week or month, depending on the number
and quality of laboratory specimens received.  If many single, unrelated sputum
specimens are received, it would be important to remind your providers of the value
of multiple specimens.  This QA activity should be recorded and maintained with
other QA records.
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7. Does your Mycobacteriology Laboratory monitor the delivery time to assure
that less than 24 hours have elapsed between specimen collection and its
arrival at the laboratory?
The challenge of this assessment tool is the reduction of laboratory turnaround time
for reporting mycobacteriology specimens.  To assure that specimens are processed
quickly and accurately, they must be received in a timely manner.  The CLIA Quality
Assurance (QA) guidelines require "accurate, reliable, and prompt reporting of test
results."  Patient treatment can be significantly enhanced by a timely acid-fast smear
report.
Specimens should be delivered to the laboratory as soon as possible after collection
so the smear and culture process can begin while the specimen is fresh.  Holding
specimens while waiting for more specimens to accumulate further delays a process
that requires three to four weeks from beginning to completion.
The date and time of collection should be required on the specimen submission
form, and the date and time of receipt should be noted by the laboratory.  A monthly
or weekly recording of these times by sample for a measured number or percent of
specimens will provide documentation. When necessary, this documentation can be
used to work with provider/clients to reduce the time of specimen delivery to the
laboratory.
In the interest of speeding delivery or transport, CDC recommends the
following: "Promote the rapid delivery of specimens to the laboratory on a daily
basis, even if this requires pickup of individual specimens to guarantee arrival
within 24 hours (41)." (See Appendix 5, The Resurgence of Tuberculosis: Is
Your Laboratory Ready?) A change in the transport system can only be effected
through close cooperation with the provider and a commitment from the laboratory
management team.
8. Does your Mycobacteriology Laboratory communicate regularly with provider
to promote understanding and cooperation?
Personal communication with providers underscores the importance of an
acceptable specimen and helps to educate the health care professional about the
laboratory specimen requirements.  Communication enhances the health care team
approach and reinforces the value of each individual's contribution to total patient
care.
9. Does your Mycobacteriology Laboratory verify that the patient's name and/or
identification number on each specimen container  matches that on the
submission form?
Your laboratory must have available and follow a written policy for proper labeling of
specimens. Specimens that are being processed, transferred and/or subcultured
must be labeled appropriately to assure the integrity of the specimens.
The specimen container should be labeled with the patient's name or number or
both.  The name or number on the container should match that on the accompanying
specimen request form.  Each specimen should be checked before processing to
assure that it is properly identified.  Specimens that are not properly identified should
be rejected.
TB specimens
should be
delivered to the
laboratory as
soon as possible,
but no longer
than 24 hours
after collection.
Specimens that
are being
processed,
transferred, or
subcultured must
be labeled
appropriately to
assure the
integrity of the
specimens.
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must report any
information
regarding the
condition and
disposition of
specimens that
do not meet the
laboratory's
criteria for
acceptability.
Report acid-fast
microscopy
results within 24
hours of
specimen receipt
in the laboratory.
10. Does your Mycobacteriology Laboratory furnish the healthcare provider with
a copy of the laboratory's:
a. Criteria for rejecting specimens?
b. Reporting policy?
10a. The provider must be given a copy of the laboratory's criteria for rejection of
specimens. The laboratory must report any information regarding the condition and
disposition of specimens that do not meet the laboratory's criteria for acceptability.
Report unsatisfactory specimens to the provider as quickly as practical, but no
later than 24 hours after receipt.
Better cooperation will be obtained if the provider understands the laboratory's
rejection policy.  Below are listed some usual reasons for specimen rejection:
a. Specimen not labeled.
b. Name on specimen and requisition form do not match.
c. Specimen leaking.
d. Insufficient quantity (urine, sputum, bronchial washing).
e. Specimen in nonsterile container.
f. Gastric specimen more than two hours old or not neutralized.  [1.5 ml of 40%
disodium.phosphate (Na HPO ) dehydrated in collection vial will neutralize2 4
45ml of specimen with pH equal to 1/10N HCl].
g. Tissue specimen more than one hour old or not refrigerated
10b. Does your Mycobacteriology Laboratory furnish the healthcare provider with
a copy of the laboratory's reporting policy?
CLIA regulations require that an adequate system is in place to report test results
in a timely, accurate, and confidential manner. Unsatisfactory specimen results
must be recorded on the report, along with the reason for rejection. The laboratory
must develop and follow a written procedure for reporting life-threatening or "panic"
laboratory results.
Positive results should be telephoned or faxed to the provider as soon as
available, so that patient management procedures can begin immediately. Delay
in this critical step can result in the dissemination of tuberculosis from infected
individuals to his or her contacts in the community or health care setting.  A single
undiagnosed, multiple drug resistant (MDRTB) case can have a major impact on
the control of TB in the community.
The following format for reporting positive acid-fast microscopy and TB culture
results is recommended:
a. Report positive microscopy results within 24 hours of specimen receipt.
b. Report results confirming the identification of M tuberculosis complex as soon
as available, but within 14-21 days of specimen receipt.
c. Report drug susceptibility results as soon as available, but within 30 days of
specimen receipt.
d. Report all final positive or negative test results in writing, including a repeat
of all preliminary reports.
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Follow all telephoned or faxed reports with a written report on the same or next
work day. Confidentiality of patient results is a special concern when telephoning
or faxing results.  The laboratorian and clinician should communicate to establish
a protocol that secures confidentiality under all circumstances.
11. Does your Mycobacteriology Laboratory include the following information on
the specimen report form:
a. Name and address of your laboratory?
b. Date and time the specimen was received in your laboratory?
c. Name and address of testing laboratory, if different from "a?"
d. Test results?
e. Drug susceptibility results, when performed?
These data elements are the minimal information required by CLIA regulations.
Your laboratory, through consultation with the medical staff and  TB Control
Division of the state, should decide additional relevant information to be included
on your report form.
Laboratories having a single HCFA certificate for multiple sites/locations must have
a system in place to identify which tests were performed at each site.
The laboratory must provide information that is necessary for proper interpretation
of the results. Therefore, the numbers of organisms viewed per field and the type
of stain used will be of interest to the physicians when reporting smear results. M.
tuberculosis complex susceptibility reports of "susceptible" or "resistant"  should
include a record of the method used, i.e., BACTEC or proportion agar method, and
also the antituberculous drugs tested and the strength or dilution of each drug
used.
12. Does your Mycobacteriology Laboratory record the number of specimens
rejected  and the reason for rejection as part of the quality assurance
program?
A written QA program will establish a routine review that requires a focused
surveillance of the quality of specimens received for laboratory testing. If there is
a pattern of sending unsatisfactory specimens, or if one provider has an unusual
number of unsatisfactory reports, it is time for action. Although some specimens
may still be rejected, you can improve the quality of specimens you receive by
eliminating any misunderstanding providers may have concerning how to properly
submit specimens.
Because some laboratories, or even some individuals within a laboratory, adopt
a policy of leniency toward specimen acceptability, the number rejected may
represent only the worst specimens, or one or two  marginal specimens may be
accepted for every one rejected. Monitor unsatisfactory specimens by recording
individual specimens rejected over time, e.g., for 1 month.  Record the number, the
source, and the reason for rejection.  Repeat the surveillance quarterly, notifying
providers with a compliance problem of ways they can improve specimen quality.
Report form
should include:
! name and
address of your
laboratory.
! date and time
the specimen was
received in your
laboratory.
! name and
address of testing
laboratory if
different than "a."
! test results.
! drug
susceptibility
results.
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13. Does your Mycobacteriology Laboratory report unsatisfactory specimens to
the provider within 24 hours of receipt?
Immediate notification of an unsatisfactory specimen may allow the provider to
collect another sample.  A delayed unsatisfactory report postpones the collection
and examination of a replacement specimen, and may result in transmission of TB
if the patient has active disease. Immediate attention to the quality of the specimen
delivers a message to the provider that an unsatisfactory specimen is important
enough to merit special handling. If it is impossible to call, it is very important to
mail the report of an unsatisfactory specimen the day that the specimen is
received.
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SAFETY
Although providing a safe work environment in the laboratory is the responsibility of
management and administration, it is the responsibility of the worker to practice safe work
habits, follow established safety procedures, and help protect the safety of himself/herself
and others.  Potentially infectious aerosols are the greatest hazard in the
mycobacteriology laboratory.  Infectious aerosols can be created in the laboratory by any
of the following manipulations:
! Pouring liquid culture or supernatant fluids.
! Using fixed volume automatic pipettors.
! Mixing fluid cultures with pipettes.
! Using a high-speed blender for homogenizing.
! Dropping tubes or flasks of broth cultures.
! Breaking tubes during centrifugation.
! Agitating specimens during processing.
! Letting drops of microbial suspension fall from a pipette onto a hard work surface.
! Centrifuging without safety carriers.
! Sonicating.
SAFETY IN THE MYCOBACTERIOLOGY LABORATORY IS EVERYONE'S
RESPONSIBILITY.
14. Does your Mycobacteriology Laboratory follow a written biosafety plan that:
a. Defines safe laboratory practices?
b. Includes procedures for handling spills and other emergencies?
14a. Federal "Bloodborne Pathogens" Regulations (17) require that a biosafety manual
be prepared or adopted by every laboratory working with infectious material.
Personnel must be advised of special hazards and are required to read and to
follow instructions on practices and procedures. This plan, along with an
explanation of its contents, must be available to employees.
14b. Does your Mycobacteriology Laboratory follow a written biosafety plan that
includes procedures for handling spills and other emergencies? 
Laboratory workers should know the appropriate action to take and persons to
contact in an emergency involving exposure to potentially infectious materials.
Since the immediate response will have an impact on the final outcome of the
incident, there needs to be rehearsal by supervisor(s) so employees will react in an
effective manner.
Any spill and/or accident which results in exposure of an employee to infectious
material must immediately be reported to the laboratory director.  Appropriate
medical evaluation, surveillance, and treatment must be made available, and a
written record maintained in the employee's personnel file, the laboratory safety
records, and/or the director's safety records.
The written
laboratory safety
plan must include
instructions on
how to handle a
spill or a
laboratory
emergency.
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personnel must
receive annual
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handling
infectious
material.
Evaluation of the
risk associated
with each
procedure is the
basis of the
laboratory
infection control
plan.
If your biosafety plan does not have detailed information on how to handle a
laboratory emergency, information may be found in the CDC LAB MANUAL,
Isolation and Identification of Mycobacterium tuberculosis: A Guide for the Level II
Laboratory, pages 140-142 (39).
15. Does your Mycobacteriology Laboratory require employees to review the
biosafety plan annually?
Federal regulations regarding occupational exposure to infectious material require
a written biosafety plan which includes the safe handling of infectious agents.
Federal regulations as they apply to medical laboratories defer to the CDC/NIH
Biosafety in Microbiological and Biomedical Laboratories manual (12). Laboratory
personnel must receive appropriate training in:
a. The potential hazards associated with the work.
b. The necessary precautions to prevent exposures.
c. The exposure evaluation procedures.
Personnel must receive annual updates or additional training as necessary for
procedure or policy changes.
16. Does your Mycobacteriology Laboratory follow a written chemical hygiene
plan that defines safe laboratory practice?
Federal regulations regarding occupational exposure to chemicals require the
development and implementation of a written chemical hygiene plan that specifically
identifies each  chemical hazard in the workplace.  Material safety data sheets
(MSDS) must be available in an easily retrievable format (18).  Employees must be
informed of the chemical hazards in the workplace and be prepared for emergency
action if exposure occurs.
17. Does your Mycobacteriology Laboratory evaluate the risk associated with the
procedures performed in your laboratory?
TB control measures for each laboratory should be based on an assessment of job
risk within the area of work. Since mycobacteriology laboratory workers may be at
increased risk of becoming infected with M. tuberculosis, they should be evaluated
periodically. A risk assessment program follows a protocol of evaluation based on
documented tuberculin skin test (TST) conversions in the laboratory.
The risk assessment should be conducted by a group that may include
laboratorians, microbiologists, hospital epidemiologists, infectious disease
specialists, or pulmonary disease specialists. Further information on developing a
risk assessment plan can be found in the Federal Register, Vol.59, No.208, October
28, 1994, Guidelines for Preventing the Transmission of Tuberculosis in Health
Care Facilities; Notices (15).
Using special engineering controls and personal protection equipment PPE), the
laboratory staff may become comfortable in their own environment and develop an
artificial sense of security. Risk assessment and abatement procedures should be
conducted for each stage of culturing mycobacteria, from opening the specimen
mailing container or delivery tray to transferring actively growing cultures.
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Additional measures may be necessary in laboratories that process large numbers
of specimens that contain M. tuberculosis and thus, have a greater potential for
exposing workers to TB.  The frequency of tuberculin skin testing (TST) of
laboratory workers using purified protein derivative (PPD) should be based on the
level of risk within the immediate work group. 
Laboratories with a history of TST conversion(s) within the past six months should
consult the State TB Control Program or the infection control physician in your
institution to develop a plan of action that meets the needs of the laboratory.
18. Does your Mycobacteriology Laboratory monitor the Mantoux tuberculin skin
test (TST)  conversion rate of personnel as a part of a risk assessment plan?
If insufficient data for determining risk have been collected on TST conversions
using purified protein derivative (PPD) among laboratory staff, these data should
be compiled, analyzed, and reviewed expeditiously.  Until such data are analyzed
and found to warrant a lesser risk rating, laboratory workers should be considered
high risk (15).
19. Does your Mycobacteriology Laboratory provide for new employees:
a. A two-step Mantoux tuberculin skin test (TST)?
b. A medical evaluation, including a chest radiograph, if TST is positive?
19a. All new employees should be evaluated at the time of employment to establish a
baseline for future tuberculin skin testing.  Use a two-step method to detect the
boosting phenomenon that might be misinterpreted as skin test conversions.  Those
with a history of vaccination with Bacillus of Calmette and Guerin (BCG) should also
be skin tested (15). 
Newly hired employees with a documented history of a positive TST, adequately
treated disease, or a history of having completed adequate preventive therapy for
infection should be exempt from TST screening.  Employees with a positive initial
skin test should be referred for chest radiograph and evaluation for possible
isoniazid (INH) prophylaxis.
19b. Does your Mycobacteriology Laboratory provide a medical evaluation,
including chest radiograph, if the tuberculin skin test is positive?
Laboratory workers with positive TST(s) should have a chest radiograph as part of
the initial medical evaluation of their TST.  If the chest radiograph is negative,
repeat chest radiographs are not needed unless symptoms develop that may be
due to TB. All information on initial and subsequent TB screening should become
a part of the employee's permanent record and maintained confidentially.
20. Does your Mycobacteriology Laboratory provide for all employees:
a. An annual Mantoux skin test on tuberculin negative employees?
b. A chest radiograph and medical evaluation if the tuberculin skin test converts
to positive or symptoms of tuberculosis are exhibited?
If insufficient data
on tuberculin skin
test (TST)
conversions
among laboratory
workers is
available, such
data should be
compiled,
analyzed and
reviewed
expeditiously.
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All laboratory
workers with
newly recognized
TST conversions
should be
promptly
evaluated for
clinically active
TB.
An aggregate
record of
employees' TST
results should be
confidentially
maintained.
c. Medical evaluation, follow-up, and counseling for any known exposure event
or PPD conversion?
d. A permanent record of skin testing results?
20a. For laboratories with careful documentation of tuberculin skin tests for a 3-5 year
period with no conversions, annual skin testing for employees is appropriate.  In a
laboratory where transmission of tuberculosis has recently occurred, tuberculin
testing should be repeated every three months until no additional conversions have
been detected for two consecutive three-month intervals (15).
20b. Does your Mycobacteriology Laboratory provide a chest radiograph and
medical evaluation if the skin test converts to positive or symptoms of
tuberculosis are exhibited?
If chest radiograph suggests tuberculosis, immediate investigation and follow-up
should be initiated, including medical evaluation and treatment.  Tuberculin skin
tests on other employees should also be initiated.  Employees with symptoms of
tuberculosis should be examined immediately by the medical staff.
20c. Does your Mycobacteriology Laboratory make medical evaluation, counseling,
and follow-up available for any known exposure event or TST conversion?
All laboratory workers with newly recognized positive tuberculin conversions should
be promptly evaluated for clinically active TB, to include a chest radiograph and
clinical evaluation.  Those without clinical TB should be evaluated for possible INH
prophylaxis according to published guidelines.
If an employee becomes tuberculin positive, a history of possible exposure should
be obtained in an attempt to determine the potential source of exposure.  When the
source of exposure is known, the drug susceptibility pattern of the particular strain
M. tuberculosis should be determined to implement appropriate preventive therapy
for the worker.
Review laboratory activities and practices for possible errors in technique.  Test all
equipment for safe operation and review safety procedures with all employees.
20d. Does your Mycobacteriology Laboratory maintain a permanent record of skin
testing results?
Results of tuberculin skin tests should be confidentially recorded both in the
individual employee health records and in a retrievable aggregate database of all
workers' TST results, so that they can be analyzed periodically to estimate the risk
of acquiring new infection in the laboratory.  This record is the basis of the risk
assessment and the development of an effective biosafety plan.  All information on
initial and subsequent TB screening should become a part of the employee's
permanent record and be maintained confidentially.
51
21. Does your Mycobacteriology Laboratory provide safety training on aerosol
prevention techniques for all employees before assigning work with TB
specimens or cultures?
To minimize the risk of infection of self and others, personnel should be selected
with care.  Employees should receive instructions on how to handle a laboratory
accident, and be instructed to report any real or suspected break in procedure to
the supervisor.
All employees with occupational exposure to infectious agents must participate in
a training program. The training must be provided during working hours at no cost
to the employee.  The training must be provided at the time of initial assignment to
tasks where occupational exposure may take place.
As the best protection against becoming infected, severely immunosuppressed
employees should avoid exposure to M. tuberculosis.  Employees with severely
impaired cell-mediated immunity (due to HIV infection or other causes) who may be
exposed to M. tuberculosis  should consider a change in job setting.  For further
information, see Federal Register, October 28, 1994, Section II-I , "Education and
Training of Health Care Workers (15)."
*22. Does your Mycobacteriology Laboratory use a Class I, II, or III biological safety
cabinet (BSC) that has been certified annually?
IF THE ANSWER IS "NO," REEVALUATE YOUR PROGRAM.
NO LABORATORY SHOULD PERFORM DIAGNOSTIC MYCOBACTERIOLOGY
WITHOUT A WELL-MAINTAINED, PROPERLY FUNCTIONING BIOLOGICAL
SAFETY CABINET.
This is the single most important equipment item necessary for reducing the
possibility of laboratory acquired infections.  If a BSC is not available or not working
properly, all mycobacteriology smear preparation and culture processing must be
referred to a Level II or III laboratory for examination. The Occupational Safety and
Work Act (OSHA) Standard (28), Section A, details the employer's responsibility for
protecting the employee from harm. (See Appendix 6 for a list of the regional OSHA
offices.).
If you have a BSC, but are not sure how effectively it is functioning, check to see
if it has been certified within the past year.  If not, have it certified..  See Resource
List (Appendix 6) for the number to call for more information.  Also, see Appendix
7(27) for assistance in  selecting, maintaining and certifying a BSC.
Personnel
working in the TB
laboratory should
be selected with
care and properly
trained.
A well-maintained
certified biological
safety cabinet is a
pre-requisite for
handling
specimens on
patients
suspected of
having
tuberculosis.
Please review the chart on the next page to determine the type of BSC you have. Note that each BSC has
a High Efficiency Particulate Air (HEPA) filter through which egress air is filtered.  If your cabinet does not
have a HEPA filter, or you are not sure, call the manufacturer for more information.
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Class I Biological Safety Cabinet:
A ventilated cabinet for personnel and environmental protection with an
unrecirculated inward airflow away from the operator.  Suitable for working with M.
tuberculosis (Biosafety Level 2/3, depending on whether pure cultures are
transferred or manipulated.)  This BSC can be used when no product protection is
required.
Class II Biological Safety Cabinet:
A ventilated cabinet for personnel, product, and environmental protection having an
open front and inward airflow for personnel protection, downward HEPA-filtered
laminar airflow for product protection and HEPA filtered exhausted airflow for
environmental protection.  This BSC is suitable for working with M. tuberculosis
(Biosafety Level 3).   Several types of Class II BSCs are available, including types
A, B1, B2 and B3. The difference in types depends on the filtered airflow and the
recirculation of air.  All types are applicable for use with biohazards, including M.
tuberculosis; B2 is designed for "total (100%) exhaust" and is not required for the
mycobacteriology laboratory.
A BSC should not be installed unless it is vented into a nonrecirculating exhaust
system or directly to the outside.  There is documentation that laboratorians have
been infected with M. tuberculosis circulating in faulty exhaust systems.
All Microbiology Laboratories providing service at the ATS Level II or Level III
must provide Biosafety Level 3 protection for the laboratory workers (12).
23. Does your Mycobacteriology Laboratory perform all manipulations on
mycobacterial specimens and cultures that may generate aerosols only in a
BSC?
Studies have shown that the risk of M. tuberculosis infection is three to five times
greater among workers in the mycobacteriology laboratory than other laboratory
workers. The production of aerosols containing tubercle bacilli can pose an
unrecognized hazard to workers who are not trained in safety practices. The most
dangerous aerosols are those that produce droplet nuclei, particles of less than
5Fm in size. These droplet nuclei remain suspended almost indefinitely in air unless
they are removed by controlled airflow or ventilation. If droplet nuclei are not
contained or eliminated, they are capable of entering a pulmonary alveolus and
establishing the primary site of infection (24).
All procedures that create aerosols should be performed only in a fully functioning
BSC in an isolation room. Examples are:  processing clinical specimens, preparing
slides, inoculating plates or  tubes, performing in-vitro tests, pouring or pipetting
cultures or supernatant fluids, mixing or diluting fluid cultures or concentrates. All
workers are responsible for the safety of themselves and others with whom they
work.
All procedures
that create
aerosols should
be performed only
in a Biological
Safety Cabinet.
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The BSC must be located in an area with limited or controlled access and with little
movement of air around the BSC while it is in operation.   The BSC should be
enclosed in a room where access is controlled while culture work is performed.  Air
currents generated by the opening and closing of doors or by workers moving
around can disturb the airflow of the cabinet.
The BSC should have the capacity to draw 75 to 100 linear feet of air per minute
(lfpm) across the entire front opening.  The magnehelic gauge on the front of the
cabinet will indicate if it is delivering the appropriate amount of air.  A strip of tissue
paper taped to the front of the BSC may be used to indicate if the direction of air
movement is correct. The space inside the BSC should be kept clean and free of
racks and stored material that may limit or distort the airflow within the cabinet.
If the airflow is less than 75 lfpm, as detected by the magnehelic gauge on the front
of the BSC, or by an air meter, the HEPA filters may be clogged and need
replacement.  The BSC should be decontaminated with paraformaldehyde
(Appendix 8) or this service can be contractually purchased before filters are
replaced.
Ultraviolet (UV) Lights:  UV lights afford a minimal protection to laboratory workers.
While it has been proven that UV lights are moderately effective for
decontaminating work surfaces and killing airborne microorganisms, they should
only be turned on in the BSC after work is completed. The UV light has little
penetrating power and is easily blocked by dust, grease, or organic material.  To
remain effective the intensity of UV lights should be checked every three months,
and the bulbs dusted or cleaned regularly with alcohol-soaked gauze.  Replace the
bulbs when the initial output is decreased to 70% of the initial reading.  Do not work
in the BSC with UV lights on or look directly at the burning bulbs. Direct or reflected
UV lights can cause severe burns to the eyes and other exposed parts of the body.
24. Does your Mycobacteriology Laboratory provide personal protection
equipment that includes laboratory coats or gowns, gloves, and face
protection?
Protective laboratory coats, gowns, smocks, or uniforms designed for laboratory
use must be worn while in the laboratory. The gowns or laboratory coats preferably
have back closures and fitted sleeve cuffs that fit snugly over the wrist.  Personal
protection equipment (PPE) is removed before leaving the laboratory for non-
laboratory areas (e.g., cafeteria, library, administrative offices.) Gowns or coats,
face protectors, gloves and other PPE worn in the dedicated culture room must be
removed and disposed of appropriately before assuming duties in the laboratory at
large. All protective clothing should be either disposed of in the laboratory or
laundered by the institution.  Protective clothing should never be taken home by
personnel.
Face protection (goggles, masks, faceshield or other splatter guards) is used when
splashing or sprays of infectious or other hazardous materials to the face are
possible.  The "dust/mist" molded face mask with adjustable metal clip across the
bridge of the nose has been widely used for respiratory protection short of wearing
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a HEPA filtered respirator.  This face mask is designed to filter 90% of particles in
the >0.5Fm range.  However, not all molded face masks are equivalent, so check
the specifications to see that the ones you are using are effective.
If there are any questions about the quality of the air provided by the present
engineering controls in your mycobacterial culture area, it is better to be safe and
use the protection provided by a HEPA filtered respirator(s).  Take immediate steps
to define the status of the engineering controls for worker safety in your laboratory,
if not known.  Engineering controls include the following:
! Separate room or suite specifically designed for mycobacterial culture
! One-pass (nonrecirculating) ventilation system
! Annually certified Class I, II, or III biological safety cabinet
! Exhaust air from BSC discharged through HEPA filters or recirculated only
after passing through filters certified to remove 99.97% of particulates 0.3Fm
or larger
! Negative pressure in culture area and a means to monitor  (Smoke tubes or
differential pressure-sensing devices can be used to monitor negative
pressure.)
! Proper airflow pattern  (Directional airflow should be from clean to least clean
area.)
! Appropriate number of air exchanges per hour  (Six to twelve room air
exchanges per hour provide removal of 99% of airborne particulates within 30
- 45 minutes.)
Selection of the maximum respiratory protection for the task is important, but
equally important is using the selected device correctly.  Both supervisors and
health care workers should be trained in the selection, proper use, and
maintenance of respiratory protection appropriate for personal use against airborne
tubercle bacilli. 
Currently, there is much discussion among safety experts over the type and kind of
respiratory protection required for culturing mycobacteria in a properly controlled
environment.  Guidelines published in the Federal Register October 28, 1994,
Section II M-c., Guidelines for Preventing the Transmission of Tuberculosis in
Healthcare Facilities (15) defer considerations for laboratories processing
specimens for mycobacterial studies (e.g., AFB smears and cultures) to criteria
specified by CDC and NIH.  (A single copy of the 3rd Edition of the CDC/NIH
Biosafety Guidelines (12) is available from CDC upon request.  See resource
list in Appendix 6.)
SPECIAL CONSIDERATIONS:
When performing high risk procedures such as cleaning liquid spills, NIOSH Type
A ($99.97% efficiency) powered air purification respirators (PAPR) with HEPA filters
are the most effective protection.  Persons responsible for cleaning up spills or
handling other emergencies with aerosol exposure risk must be trained and fit-
tested for respirator use.
Face protection
gives an
additional
measure of safety
when splash or
sprays of
infectious
materials are
possible.
56
In certain clinic and hospital settings, the laboratorian may be present or involved
in the collection of expectorated or induced sputum specimens.  Employees who
have been adequately trained and fit tested with National Institute of Safety and
Health (NIOSH) Type C ($95% efficiency) respirators will be protected from TB
infection.  Strict  management procedures and reliable engineering controls are
needed to reduce the risk of exposure (15).
25. Does your Mycobacteriology Laboratory decontaminate all personal protection
equipment before it leaves the laboratory area?
Reusable laboratory clothing should be placed into covered containers or laundry
bags and autoclaved before laundering.  Gloves, disposable masks and other
disposable clothing may be discarded when contaminated or when single usage is
complete. Disposable gloves should never be washed for reuse. CDC approved
methods for decontaminating disposables include autoclaving, chemical
disinfection, and incineration.
The laboratory must have a method for decontaminating all laboratory wastes,
preferably within the laboratory. Autoclave indicators (e.g., spore strips) should be
used to monitor autoclave function.
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LABORATORY PRACTICE
With the exception of aseptically collected specimens, most clinical mycobacteriology
specimens are contaminated to varying degrees by more rapidly growing organisms.
These specimens must be subjected to harsh decontamination and digestion procedures
that liquefy organic debris and eliminate unwanted normal flora organisms. The success
of these procedures depends on:
! The resistance of the mycobacteria to strongly digesting solutions
! The length of time the mycobacteria contact the digesting-decontaminating agent
! The temperature buildup in the specimen during centrifugation
! The efficiency of the centrifuge to sediment the mycobacteria
All operating procedures should be designed for optimum isolation of acid-fast organisms.
You  must develop your own standard operating procedures based on the standards
recommended by CDC and other expert mycobacteriologists. Also, update as necessary.
The proficiency and the dedication of staff working in the laboratory makes all of the
difference in the success of the mycobacteriology program. One laboratory (Appendix 2)
reduced the average turnaround time of its TB specimens processing from 40 days to 10-
22 days in sixteen months (2).  They credit the following factors as making the difference:
! Having  a determined and dedicated laboratory supervisor and staff
! Working with the mail delivery service to arrange for timely receipt of specimens in
the laboratory
! Reporting  testing results via telephone and fax, followed by a written report
! Starting drug susceptibility testing immediately (usually daily) after
isolation/identification procedures
! BACTEC read 7 days a week;  NO batching
Study your program.  You, too, can report a SUCCESS STORY!
26. Does your Mycobacteriology Laboratory participate in an approved proficiency
testing program?
Laboratories performing non-waived tests must participate in an approved
proficiency testing (PT) program in each of the specialties (microbiology) and
subspecialties (mycobacteriology) for which they are certified. Preparation and
examination of direct acid-fast smears are classified as moderate complexity
testing; preparation and examination of concentrated smears, culture, identification,
and susceptibility testing are classified as high complexity testing. 
Therefore, laboratories performing any one or combination of these tests must
subscribe to an approved mycobacteriology PT program containing two testing
events per year, with five specimens per event.  PT programs are approved
annually, so the list of approved PT programs may change from year to year.
Check with your laboratory inspection agency to obtain a current list of approved PT
programs.  It is the laboratory's responsibility to enroll in an approved PT program
which is appropriate for the level of testing provided for patient specimens.
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Witten standard
operating
procedures must
be readily
available and
followed by all
technical
personnel.
Label all reagents
and chemicals
before storage.
Laboratories
processing fewer
than 10 smears
should consider
sending
specimens to a
reference
laboratory.
PT samples must be tested in the same manner as patient specimens, with no
unusual or extraordinary consultation or attention. They must be tested with the
same frequency as routine samples, and the staff may not consult with personnel
from other laboratories concerning the samples. The samples may not be referred
to another laboratory for testing. The individual performing the testing and the
laboratory director must certify that the PT samples were routinely integrated into
the daily workload.  PT records must be retained for two years.
27. Does your Mycobacteriology Laboratory follow standard operating procedures
and maintain the results of quality control for each test procedure for two
years?
Written standard operating procedures for all methods and tests must be readily
available and followed by all technical personnel.  The director must approve, sign
and date  all modifications to procedures, indicating approval.  If the director
changes, procedures must be reapproved.
The dates of initial use and discontinuance of each procedure must be
documented.  A copy of a discontinued procedure must be retained for two years
after the date of discontinuance.  The laboratory must follow a written quality control
protocol to monitor and evaluate the quality of the analytical testing process.  All
quality control readings must be documented and the records maintained for a
minimum of two years.
28. Does your Mycobacteriology Laboratory label all reagents to indicate identity,
strength or concentration, storage requirements, preparation and expiration
dates?
Reagents, solutions, culture media, control materials, calibration materials and
other supplies must be labeled to indicate:
a. Identity
b. Titer, strength, or concentration, when significant
c. Recommended storage conditions
d. Preparation and expiration dates
e. Date received and date opened for purchased reagents
*29. Does your Mycobacteriology Laboratory prepare and examine >10 acid-fast
smears per week?
It is recognized by the ATS and CDC that to maintain proficiency in smear
examination (acid-fast microscopy), laboratories should examine a minimum of 10-
15 smears a week.  Specimens must be processed (decontaminated and
concentrated) to provide meaningful stain results.  Positive and negative control
smears should be stained at least once each day of use to provide an indication of
stain performance.
Laboratories that examine fewer than 10 acid-fast smears per week should consider
using a reference laboratory for smear examination. Because of the reduced
sensitivity of smear examination, all sputa collected for examination for acid-fast
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bacilli should be tested in a laboratory with the capacity for culturing mycobacteria.
With a secure and reliable transportation system and 24 hour service, the practical
aspect of examining acid-fast smears must be questioned.
30. Does your Mycobacteriology Laboratory use the fluorochrome stain as the
primary acid-fast stain for smears made from the patient's specimens?
The fluorochrome method is preferred to screen for acid-fast bacilli because of
increased sensitivity and the ease of reading the smears.  Low power magnification
allows more rapid examination of smears, because a greater area of the slide can
be examined at one time.  Laboratories need not confirm results of positive
fluorochrome stains with the Ziehl-Neelsen or Kinyoun's acid-fast stain unless there
is doubt about results of the initial smear.  The routine use of the fluorochrome
stained smear for the examination of TB specimens is recommended by both the
CDC and the Association of State and Territorial Public Health Laboratory Directors
(ASTPHLD).  Use of the Ziehl-Neelsen or Kinyoun's acid-fast stain is recommended
only to detect AFB or contamination in cultures.
31. Does your Mycobacteriology Laboratory check reactivity of fluorochrome stain
each day of use by staining and examining known acid-fast and non-acid-fast
organisms?
Laboratories performing acid-fast staining procedures in mycobacteriology
laboratories should check the fluorochrome acid-fast stain for positive and negative
reactivity each day staining is done.  The Clinical Microbiology Procedures
Handbook (25) published by the American Society for Microbiology(ASM), describes
a method for preparing and examining acid-fast control slides.  Control slides for
acid-fast stains are also commercially available.
ASM recommends that the stained control slides be reviewed before the patient
smears are read to confirm that the acid-fast mycobacteria are staining properly.
Record the results of the control slides.  If they are acceptable, evaluate the patient
smears.  If the control slides are unacceptable, review procedures and reagent
preparations.  Unacceptable control slides include the following:
a. Negative control fluoresces
b. Positive control does not fluoresce, or is dull
c. Background is not properly decolorized or fluoresces
When the problem is resolved, restain the original control slides, as well as all
patient slides from the problem run (25) .  
An increase of >2% in the number of specimens positive by smear, but negative on
culture suggests the possibility of false positive acid-fast smears.  All components
of the digestion and staining procedure, including the water, should be examined
as sources of contaminating mycobacteria.  Digestant solutions, buffer or water
diluents, bovine albumin solution or powder, and staining reagents are examples
of possible sources of contamination by all mycobacteria (including M.
tuberculosis).  (See Appendix 9.)  
Routine use of
the fluorochrome
stain to screen for
acid-fast
organisms is
recommended by
CDC and
ASTPHLD.
Acid-fast and
non-acid fast
controls must be
stained and
examined each
day patient
smears are
stained and
examined.
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The number of
tubercle bacilli in
pulmonary
secretions is
directly related to
the risk of
transmission of
disease.
Do not try to
speciate
mycobacteria
based on
microscopy
alone.
If you question smear examination results, have a second, experienced reader
examine the slides (36).
32. Does your Mycobacteriology Laboratory examine acid-fast smears the day
they are stained?
In addition to reducing turnaround time by reading fluorochrome stains the day they
are prepared, fluorochrome-stained smears should be observed within 24 hours of
staining because the fluorescence may fade.  Stained smears that cannot be read
immediately should be stored at 2-8 C until read, but no longer than 24 hours.o
33. Does your Mycobacteriology Laboratory report an approximation of the
number of acid-fast organisms viewed on the slide?
Staining of specimen smears is used to assess patient infectivity, because the
smear demonstrates a semi-quantitative estimate of the number of bacilli being
excreted.  A quantification of the numbers of acid-fast organisms per field should
be rated 1+ - 4+(1,24,36).  The number of tubercle bacilli in pulmonary secretions
is directly related to the risk of transmission.
METHOD FOR REPORTING NUMBERS OF ACID-FAST BACILLI OBSERVED IN
STAINED SMEARS*(Appendix 1)
Number of AFB CDC Method
Observed Report
None Negative for AFB (-)
1-2/300 fields Number seen (±)**
1-9/100 fields Average No./100/F (1+) 
1-9/10 fields Average No./10F (2+)
1-9/field Average No./F (3+)
>9/field >9/F (4+)
*Examination at 800-1000X is assumed. Magnification less than 800X should clearly
be stated.  If microscopist uses consistent procedure for smear examination,
relative comparisons of multiple specimens should be easy for the clinician,
regardless of magnification used.  To equate numbers of bacilli observed at less
than 800X with those seen under oil immersion, adjust counts as follows:  for
magnifications about 650X, divide by 2; near 450X, divide by 4; near 250X, divide
by 10, e.g., if 8 AFB per F were seen at 450X, the count at 1000X would be about
2/F (8 ÷ 2) (36). 
**Counts less than 3/300F at 800-1000X are not considered positive; another
specimen (or repeat smear of same specimen) should be processed if available.
Although M. tuberculosis may present characteristic morphology as viewed on  the
microscope slide (e.g., cording), other species may do the same; therefore, do not
use microscopy alone to identify individual species of mycobacteria.
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*34. Does your Mycobacteriology Laboratory telephone, fax, or electronically report
all positive acid-fast smear results to the health care provider as soon as
results are known, but within 24 hours from specimen receipt?
To halt the continuing spread of tuberculosis across the United States and to help
control transmission within the community, laboratories must recognize the urgency
and optimize their procedures to report results of acid-fast smears, culture
identification, and drug susceptibility tests to clinicians. Maintain a written record of
direct calls and a record of the fax reports of smear results as a part of the QA
record. A hard copy of the smear examination results should follow within 24 hours.
BOTH CDC AND ASTPHLD RECOMMEND REPORTS OF POSITIVE SMEAR
RESULTS BY TELEPHONE, FAX OR ELECTRONIC MAIL WITHIN 24 HOURS OF
RECEIPT OF THE SPECIMEN IN THE LABORATORY. EVERY LABORATORY
SHOULD BE COMMITTED TO COMPLYING WITH THIS IMPORTANT
REPORTING MECHANISM. THE MEDICAL COMMUNITY EXPECTS THIS
RESPONSE.
On smears in which no acid-fast bacilli are seen, report "Negative for acid-fast
bacilli" by hard copy only.  Reserve direct communication for positive results.
35. Does your Mycobacteriology Laboratory record the date and time positive
results are telephoned, faxed, or electronically reported to health care
provider(s)?
Logging telephone calls of positive results to physicians or maintaining a copy of fax
results is an integral part of the quality assurance plan.  Documentation is
necessary to establish this link in the system.  Since telephoned results are critical
to patient care, it is important to establish the authority and record the identity of the
person receiving the report. Confidentiality of the test result must be maintained.
The following information must be documented when telephone reports are given:
a. Patient name
b. Type of culture or stain
c. Specimen type and date obtained
d. Findings
e. Person called
f. Person making the call
g. Date and time of call
To meet CLIA requirements for reporting results, written procedures must be
developed for reporting imminently life-threatening results or panic values.  The
presence of AFB in a smear should be considered a critical value and handled as
such.  The individual who orders or uses the test result must be alerted
immediately.
Report positive
acid-fast smear
results within 24
hours of
specimen receipt.
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36. Does your Mycobacteriology Laboratory telephone, fax or electronically report
all positive acid-fast smear results to the public health department as soon as
the results are available, but no longer than 24 hours from specimen receipt?
Report patients who are suspected on clinical grounds of having tuberculosis or
those with acid-fast bacilli (AFB) present on smears to the local health department
promptly so that appropriate public health management (including contact
investigation) can be initiated.  If TB is to be controlled, it is imperative that
immediate and appropriate responses to new cases be initiated by infection control
experts and public health practitioners. 
37. Does your Mycobacteriology Laboratory deliver or mail a written microscopy
report to the health care provider within 48 hours of specimen receipt in the
laboratory?
The report must be sent promptly to the authorized person ordering or using the
result. Interim reports of smear positive and smear negative are exceedingly
important in the management of patients, whether they are new patients, recovering
patients, or not infected. The laboratory manager can assist in this effort by having
a written procedure that sets a time limit for reporting acid-fast smear results and
assuring the staff are meeting the requirement.
Frequently, an interim or preliminary report will contain significant, but not definitive,
information.  This report should be identified as interim or preliminary, with a note
that the final report will follow.  The final report should repeat preliminary findings.
All reports must contain proper patient identification.
38. Does your Mycobacteriology Laboratory maintain all patient reports and test
records for two years?
The original report or an exact duplicate must be retained for two years. The "exact
duplicate" need not be paper, but may be retrieved from a computer system,
microfilm or microfiche record, so long as it contains the exact information sent to
the individual ordering the test or using the test results.  Reports must be
maintained in a manner that permits identification and timely accessibility.  The
original test requisition and test records must be retrievable for two years.
39. Does your Mycobacteriology Laboratory assure confidentiality of all patient
information?
If the laboratory uses a laboratory information system, i.e., an electronic reporting
system, what security measures have been instituted to ensure that transmitted
reports go directly from the device sending reports to only the individual ordering the
test or using the test results?  Selective access by codes to the laboratory
information system will prohibit unauthorized users from gaining entry.
Your laboratory must communicate with users for correct addresses and routing
codes to ensure that written reports are accessible as soon as possible. A list of
names and addresses of "authorized persons" is helpful to individuals reporting
preliminary results.  A written policy for reporting by telephone, fax, or electronic
mail is necessary to meet the CLIA intent for confidentiality of reporting.
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LEVEL I LABORATORIES ANSWER 40 & 41
40. Does your Mycobacteriology Laboratory limit access into the laboratory when
specimens are being processed?
The TB laboratory must meet specifications of biosafety level 3 and doors must be
closed while work is in progress in the BSC.  If the BSC is shared for work with
other microorganisms, limit access to the area during smear preparation to those
who need to be present.  After the specimens have been disinfected or
decontaminated/concentrated and the smears are drying, continue work in the area.
Heat fix the smears as soon as possible.
*41. Does your Mycobacteriology Laboratory send all specimens to a full service
laboratory for culture within 24 hours of receipt?
The Level I laboratory performing only smear examination should immediately send
5-10ml of specimen to a reference laboratory for culture.  Preliminary results of
smear examination can be reported to the physician/provider, including information
that the specimen has been sent to a reference laboratory for culture.
All specimens collected to examine for M. tuberculosis should be cultured.  The
acid-fast smear alone is not a reliable predictor of disease due to M. tuberculosis.
Reports estimate that 30-50% of patients with pulmonary tuberculosis have
negative sputum smears.  For a definitive diagnosis of tuberculosis the bacillus
must be isolated and identified.  Laboratories with no capacity for identification
of mycobacteria can seriously delay reporting of a case of tuberculosis by
delaying the culture of the specimen(s).
! False negative smear reports on single sputum specimens can be misleading.
Sputum for smear and culture collected on 3-6 consecutive days provides
better information.
! Preparing and examining AFB smears, culturing specimens, and sending
original positive slants, plates, or bottles to a reference laboratory for further
work unnecessarily delays identifying M. tuberculosis.
! Preparing and examining AFB smears, inoculating cultures on media and
sending mycobacterial subcultures (pure isolates) to a reference laboratory
will unnecessarily delay identification of M. tuberculosis. For best results, send
specimens to reference laboratories without delay.
All specimens
collected for
examination for
TB should be
cultured.
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It is
recommended
that laboratories
culturing fewer
than 20
specimens per
week send
specimens to a
reference
laboratory.
Every effort must
be taken to
assure that no
contamination or
carry-over occurs
between
specimens.
LEVEL II LABORATORIES ANSWER QUESTIONS 1-39; 42-80
*42. Does your Mycobacteriology Laboratory process and culture  >20 specimens
per week?
Proficiency in culture and identification of M. tuberculosis may be maintained by
digestion and culture of 20 specimens per week, provided adequate controls are
used.  Application of state-of-the-art laboratory technology for the laboratory
identification of M. tuberculosis is costly and requires sophisticated instrumentation
and highly trained laboratorians.  Available rapid methods require high specimen
numbers to performed reliably and cost-effectively. Compliance with CLIA
regulations, particularly those relating to safety, quality assurance, and proficiency
testing, are also fiscal considerations for mycobacteriology laboratories.   
The American Thoracic Society recommends that the full spectrum of bacteriologic
support be concentrated in only a few laboratories in a given community or region
where professional expertise and complete and safe facilities are available.  Thus,
laboratories with a low volume of work should refer specimens/cultures to
laboratories that have chosen to maintain capabilities in mycobacteriology.  This will
save the time, effort, and expense of setting up and maintaining quality control
standards for tests that are performed only rarely (1).  If your laboratory cannot
meet today's standards for quickly and accurately identifying and reporting M.
tuberculosis complex, consider one of the alternatives:
a. Update your laboratory equipment and procedures to shorten the time from
collection until reporting.
b. Refer your TB specimens to a laboratory that meets strict standards for quality
testing and rapid reporting.  
43. Does your Mycobacteriology Laboratory take steps to eliminate cross-
contamination between cultures?
There is no substitute for meticulous technique when working with live
microorganisms.  When culturing M. tuberculosis, many opportunities exist to
introduce contaminating organisms from the environment or, an even greater
hazard, from another specimen.  The laboratory technique used in the TB laboratory
must be attuned to perfection.  Every effort must be taken to assure that no
contamination or carry-over occurs.  In a  retrospective study, 16% of 140 cases of
MDR tuberculosis were the result of laboratory cross-contamination (35)!  Transfers
or inoculation of cultures must be accomplished by using individual transfer
pipettes, single delivery diluent tubes or disposable labware to ensure that the
specimen integrity is maintained.  Examine your procedure and make certain there
is no opportunity for cross-contamination between specimens.  Be suspicious of
several successively positive specimens or of a culture with very few colonies that
follows a specimen culture that is 4+ positive.  Meanwhile, use the following
suggestions to protect the integrity of your specimens:
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a. Perform all culture work, especially liquid culture, over towels soaked with
disinfectant spread over the work surface.  Working with a tray lined with
disinfectant-soaked towels permits easy disposal of all autoclavable material
at the same time.  Towels will absorb any droplets or splatters that may
inadvertently occur during culture manipulations.
b. Discard contaminated fluids into a splash-proof container.
c. Use aseptic technique when removing caps from tubes, never laying them on
a tabletop.  Work with only one specimen or culture open at a time.
d. Add diluent to centrifuge tubes from individual tubes without the lip of the tube
touching or creating an aerosol.  Pouring from a common container is an
opportunity to cross-contaminate cultures.
e. To avoid droplet aerosol cross-contamination, open tubes one line at a time.
Opening several tubes at once creates an opportunity for crossover of droplet
nuclei.
f. Pipette bovine serum albumin or sterile buffer with a sterile pipette.  Do not
pour from the tube or bottle into centrifuged sediment because splash-back
can and does occur.
g. Make transfer and dilutions with sterile pipettes.
h. Make smears after all inoculations are complete.
i. Daily, after completing culture procedures, wipe down the work surfaces
inside the BSC, and the tabletops, and centrifuges with towels moistened in
a disinfectant with tuberculocidal action (note claims on the label).
j. Autoclave all discard materials daily, after culturing is completed.
k. Perform daily QC on the BACTEC instrument.
l. Change BACTEC needles daily.
m. Keep BACTEC media trap, filters, and tubing clean.
n. Review all cultures which are only BACTEC positive to ensure that there has
been no cross-contamination.
44. Does your Mycobacteriology Laboratory routinely process and culture
specimens seven days a week?
Laboratories with no weekend work seriously delay reports of identification and
susceptibility testing because they are not operational for 28.6% of the time.  Added
to this built-in delay are the practices of batching until a certain number of
specimens for mycobacterial testing have been received or only processing 3 or 4
days per week.  
With the use of the BACTEC and other rapid methods, more efficient and timely
reporting of positive identification and drug susceptibility results can occur if a 7 day
work week is adopted.  Many institutions, hospitals in particular, have expanded
their laboratory coverage out of necessity.
Would your patients benefit from weekend coverage in mycobacteriology?  Have
you considered an alternative work schedule in your laboratory?
More efficient and
timely  
reporting of
positive results
and  drug
susceptibility 
results can occur
if a 7 day work
week is adopted.
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45. Does your Mycobacteriology Laboratory use a refrigerated centrifuge(s) at a
relative centrifugal force (RCF) of  at  least 3000 for 15 minutes to process
mycobacterial specimens for culture? 
Since heat buildup is extremely destructive to viable mycobacteria, it is highly
recommended to use only refrigerated centrifuges as a means to prevent excess
heat buildup.  Also,  a RCF of at least 3000 must be held for 15 minutes to achieve
95% sedimentation rate and effectively concentrate M. tuberculosis from sputum
specimens.  The centrifuge must be monitored for centrifugal efficiency and the
RCF posted and known by the operating staff.  [The staff must understand the
difference between "revolutions per minute" (RPM) and "relative centrifugal force"
(RCF or gravity force)]. Many old centrifuges still used in mycobacteriology
laboratories commonly spin at 2300-3000 RPM (1500-2000 RCF); most users of
such equipment centrifuge their digested specimens for only 15 minutes and thus
attain theoretical sedimenting efficiencies ranging from 75-84% that may be further
reduced by lethal heat buildup (24).
Angle head rotors are preferred for use in mycobacteriology to reduce frictional air
resistance during centrifugation.
46. Does your Mycobacteriology Laboratory use only safety carriers equipped
with O-ring closures when centrifuging specimens?
To reduce aerosol hazard from breakage during centrifugation, only aerosol-free
safety cups with domed O-ring sealed closures should be used in mycobacteriology
laboratories.  Because tubes may leak or break, open the safety carriers and
remove tubes only inside a BSC.  
Microcentrifuges should not be placed under the BSC for operation because air
convection during operation compromises the integrity of the BSC.  Safety cups for
microcentrifuges are now available.
A good discussion of centrifugal safety and efficiency can be found in PUBLIC
HEALTH MYCOBACTERIOLOGY:  A Guide to the Level III Laboratory, pp 31-35
(24).
47. Does your Mycobacteriology Laboratory prepare, stain, and examine acid-fast
smears from all specimens sent for mycobacterial culture?
Routine procedure for the examining any specimen submitted to the laboratory for
TB culture should include AFB smear preparation and examination.  AFB smear
findings will provide information of value to the physician whether they are positive
or negative.  Microscopic observation of acid-fast bacilli in stained smears may be
the first evidence that mycobacteria are present in a clinical specimen.  
Although smear examination is less sensitive than the culture method for detecting
mycobacteria and does not allow the observed organisms to be identified to the
species level, it is the easiest and most rapid procedure that can be performed in
the laboratory. AFB smears can be helpful in several ways:
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! Provide a presumptive diagnosis of mycobacterial disease, making it possible
to rapidly identify most infectious patients (i.e., those that are smear positive).
! Use to follow the progress of tuberculosis patients on chemotherapy.
48. Does your Mycobacteriology Laboratory have an isolation room for
mycobacteriology that is separate from the rest of the laboratory?
Laboratories performing mycobacteriology at ATS/CDC Level II or III must meet
CDC/NIH Biosafety Level 3 requirements.  An appropriate secondary barrier is
provided by separating the mycobacteriology laboratory from areas open to
unrestricted traffic flow within the building.  Within this room, in which the BSC is
located, specimens that may contain M. tuberculosis are decontaminated,
centrifuged, and cultured.  Smears are also prepared and cultures are inoculated
in the BSC.  
An "isolation room" prevents the escape of droplet nuclei from the room, thus
preventing entry of M. tuberculosis into the corridor and other areas of the facility.
It provides an environment that will allow reduction of the concentration of droplet
nuclei through various engineering controls, primarily through negative air pressure
and an efficiently operating BSC.  Negative pressure ventilation dilutes and
removes aerosolized pathogens and will prevent the contaminated room air from separate from the
flowing into other rooms. The air flow into the operating BSC will create a proper
egress for contaminated air into the HEPA filter system, which will then be emitted
from the building or recirculated after proper filtration.
49. Does your Mycobacteriology Laboratory keep the laboratory doors closed
when mycobacterial specimens are being processed?
Passage through two sets of self-closing doors is the basic requirement for entry
into the mycobacteriology laboratory from access corridors or other adjoining areas.
A clothes change room (optional shower) may be included in the passageway.  The
door should always be closed, and access to the area should be limited to the
laboratory staff performing the work.
*50. Does your Mycobacteriology Laboratory have a one-pass (non-recirculating)
ventilation system that establishes an airflow pattern, moving from clean (e.g.,
corridor) to least clean area (e.g., isolation laboratory)?
The purpose of a one-pass system is to prevent the spread of contaminated air to
uncontaminated areas.  The direction of air flow is controlled by creating a lower
(negative) pressure in the area into which flow is desired.  Negative pressure is
attained by exhausting air from the area at a higher rate than it is being supplied.
The level of negative pressure necessary to achieve the desired air flow will depend
on the physical configuration of the ventilation system and area, including the air area of higher
flow path and flow openings, and should be determined by an experienced
ventilation engineer on a case-by-case basis.  Six to twelve air changes per hour
are acceptable and provide removal of 99% of  airborne particulate within 45
minutes (24).
Smears are
prepared in the
safety of the BSC,
preferably in a
room that is
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laboratory.
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The isolation room should have negative pressure relative to the adjacent area with
air moving from an area of low infectivity to an area of higher infectivity.  The work
area should contain no air sources such as open windows or through-the-wall
ventilation ducts.  Doors between the isolation room and other areas should remain
closed except for entry or egress and there should be a small gap of 1/8 to 1/2 inch
at the bottom of the door to provide an air flow path.  A person with expertise in
ventilation or industrial hygiene should work closely with the infection control
committee and microbiology staff to establish air handling guidelines (15).
51. Does your Mycobacteriology Laboratory monitor the environmental conditions
in the isolation room annually to determine the number of air exchanges and
the negative pressure status?
Review the air handling systems annually, and record the findings as a part of your
preventive maintenance.  Documentation of professional inspection and analysis
will support the laboratory findings.  After any modification in the general air
handling or ducting system, environmental engineers or experts in ventilation
engineering should reinspect the mycobacteriology ventilation system to determine
the air quality in the area.  Record the event as you would any equipment
maintenance event.
Use smoke tubes or an air velocity measuring device with smoke tubes to monitor
negative pressure on a quarterly basis in the mycobacteriology laboratory.  Record
your findings as part of the preventive maintenance monitoring plan.  Check and
record the reading of the magnehelic gauge on the BSC as a daily operational QC
check.
A simple way to daily ensure that a room has negative air pressure is to tape short
strips of tissue paper at the base of the door and on air duct grills.  The directional
movement of the paper strips serves as a constant indicator of the direction of the
air flow.
52. Does your Mycobacteriology Laboratory control access to the laboratory when
working with mycobacterial specimens?
A secondary containment strategy to reduce the hazard of working with viable
mycobacteria in a Biosafety Level 3 containment area is to control the access to the
culture area.  This is done by restricting access except to persons whose presence
is required for program or support purposes.
*53. Does your Mycobacteriology Laboratory inoculate all digested/
decontaminated, concentrated sediments into a selective broth, e.g., the
BACTEC System, for the primary culture?
Laboratories are being challenged to use liquid culture as the primary method for
isolating M. tuberculosis.  Primary culture in a selective broth medium enhances the
growth of M. tuberculosis and is preferred to culture on solid media alone.  The
BACTEC 460 TB radiometric system (Becton-Dickinson, Sparks, MD) is being used
with great success in many hospitals and reference laboratories.  This system uses
liquid growth medium containing radiolabeled palmitic acid as the substrate, and
improves recovery and decreases the time required for detection of mycobacteria.
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Growth of mycobacteria is detected within 7-14 days by measuring the CO14 2
released from the substrate by metabolizing mycobacteria.  Once growth is
detected, the organism can be identified by using specific procedures developed
to rapidly identify M. tuberculosis.  The sensitivity and specificity of the BACTEC
method of isolation have proven to be the highest of any method to date to detect
the strains of the M. tuberculosis complex quickly and accurately.
Advantages:
! Average time from primary inoculation to detection of positive growth is 8-12
days
! Isolation and identification of M. tuberculosis complex requires 4-5 days after
growth detection
! Primary drug susceptibility testing from broth culture requires 4-6 days
! Growth occurs more often in liquid medium than on Lowenstein-Jensen or
other solid media
Disadvantages:
! Capital investment for instrumentation in laboratories culturing fewer than 20
cultures per week is impractical
! The liquid culture method is hazardous because of potential for needle sticks
! The disposal of radioactive waste material is expensive and troublesome
! The method is labor intensive
The N-acetyl L-cysteine-sodium hydroxide (NALC-NaOH) digestion-decontamination
method is the procedure of choice for preparing specimen for inoculation to
BACTEC. The sodium hydroxide, oxalic acid, and sodium lauryl sulfate methods
can be used, but the Zephiran-trisodium phosphate, benzalkonium chloride, or
cetylpyridium chloride methods cannot be used with the BACTEC procedure, as the
residual quantities of these substances in the inoculum inhibit mycobacterial growth
in the BACTEC system (29).
Contamination may be indicated by any sudden increase in the growth index (GI)
reading or by the presence of turbidity.  Growth of AFB should be confirmed by a
Ziehl-Neelsen or Kinyoun's stain.  M. tuberculosis should not be reported based on
smear examination only.  Rapid identification of M. tuberculosis complex can be
made from a concentrated sample of a primary BACTEC 12B broth culture that is
AFB positive.  Cross-contamination of BACTEC culture vials because of inadequate
heat sterilization of the sampling needle has been reported and may pose a
problem (25).
The Septi-Chek AFB System (Becton-Dickinson, Cockeysville, MD) is a biphasic
culture system, consisting of modified Middlebrook 7H9 broth and a three-section
paddle containing chocolate, an egg-based medium, and modified Middlebrook
7H11 solid agar. Comparison of Septi-chek growth to growth of mycobacteria in
BACTEC revealed that while the sensitivity was similar, the average time for the
detection of mycobacteria from BACTEC was 11.8 days, Septi-Chek 18.8 days, and
Lowenstein-Jensen (L-J) 23.5 days (32).  The Septi-Chek system does not require
specialized instrumentation or the use of radioisotopes.
Both the Septi-Chek and the BACTEC systems are superior to conventional
methods (L-J) for recovery and time to detection of mycobacterial growth (32).
Primary culture in
a selective broth
medium
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growth of TB and
is preferred to
exclusive culture
on solid media.
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Other systems [such as BACTEC 9000 and Midget System (Becton-Dickinson),
ESP-AFB (Difco) and the BacT-Alert (Organon Teknika Corporation, Durham, NC)]
are in development and should be available soon.
54. Does your Mycobacteriology Laboratory inoculate all specimens not requiring
decontamination into a broth, e.g., BACTEC System, for the primary culture?
Specimens collected aseptically or from normally sterile sites can be inoculated
directly to BACTEC 12B vials without being decontaminated. Aseptically collected
specimens with volume greater than 10ml should be centrifuged at 3000 RCF
before inoculation.  Specimens that are thick or mucoid should be liquefied before
centrifugation.
55. Does your Mycobacteriology Laboratory inoculate digested/decontaminated,
concentrated sediments of mycobacterial specimens to at least one solid
medium?
In addition to the inoculation of liquid culture medium good laboratory practice
requires that at least one selective solid medium be inoculated at the same time.
Growth on solid media can be used to detect mixed colony morphology and to
provide a source for isolation of a pure culture.  If there is no growth on the original
solid medium, a second solid medium should be inoculated from the primary
BACTEC vial at the time the AFB smear(s) is prepared (growth index >100 units).
Compare growth on BACTEC with results on solid medium and the original AFB
smear for quality control purposes.
56. Does your Mycobacteriology Laboratory inoculate a negative control each day
specimens are inoculated?
Inoculating a negative control under conditions identical to those used for the
specimens assures that conditions are appropriate for recovery of M. tuberculosis,
and may indicate if contamination has been introduced during the culture process.
Record results as a part of the quality control record.  Any growth of mycobacteria
on the negative control is an alert for immediate investigation of positive cultures
on that process run, including notification of physician(s) if questionable results
have been reported.
57. Does your Mycobacteriology Laboratory perform direct drug susceptibility
testing with the primary drugs using the concentrated sediment of smear
positive specimens?
The BACTEC procedure for susceptibility testing against primary drugs
[streptomycin, isoniazid, rifampin, and ethambutol (SIRE)] provides the most rapid
results of any method in use today. Both direct and indirect susceptibility tests may
be performed using the BACTEC method. The BACTEC direct susceptibility tests
were reportable in 10.7 days from more than 67% of AFB smear positive cultures,
and from 86% of M. tuberculosis culture positives (33).  Agreement of the BACTEC
direct susceptibility test results with those obtained by the conventional techniques
has been reported to be very high (22).
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When using "conventional" agar testing methods, direct susceptibility testing
against primary drugs, SIRE, should be performed on all initial smear positive
specimens.  Both the agar dilution method and the disk-elution method have been
used with success in laboratories performing direct susceptibilities to primary drugs.
The disk-elution method provides equivalent results without errors associated with
weighing, diluting, or labeling and provides a method for preparing only the number
of plates needed for short-term use.  The direct method for testing susceptibility
from the initial concentrated sputum specimen is preferred since the indirect
method may not represent the true patient cell population.  If the indirect method
from growth on solid medium is used to test susceptibility, the inoculum should be
prepared from cells collected by a swipe across the medium to maintain as much
as possible a representation of patients original microbial population. 
Read and report results of drug tests on Middlebrook 7H11 medium at three weeks.
If the colonies are fully matured and only if they show resistance, results may be
reported in less than three weeks.  Although colonies may be fully matured on
control media in less than three weeks, "drug susceptible" reports should not be
sent until the third week, because resistant colonies often grow more slowly than
susceptible ones and may not be visible until the third week.
Pyrazinamide (PZA) is a primary drug, and current practice requires that isolates
should be tested for susceptibility.  PZA susceptibility is difficult to test in vitro (22).
The effect of the drug can be demonstrated only in an acidic medium that does not
adequately support the growth of many M. tuberculosis isolates.  Using an inoculum
from a fresh, actively growing culture, the BACTEC provides a method for testing
PZA susceptibility.  If the BACTEC system is not available, it is recommended that
PZA be tested only in reference laboratories.  NOTE:  Only M. tuberculosis is
susceptible to PZA.  M. bovis, M. bovis (BCG) are resistant to PZA,  as are all other
mycobacteria species except M. tuberculosis.
58. Does your Mycobacteriology Laboratory use a control strain of M. tuberculosis
susceptible to all antimycobacterial agents being tested, each time a drug
susceptibility test is performed?
The laboratory must check susceptibility of each daily run with a strain of M.
tuberculosis susceptible to all antimicrobial agents tested. M. tuberculosis, strain
H37Rv, is completely susceptible to the SIRE drugs and pyrazinamide (25).
QC strains should be tested under conditions identical to those of the test strains
to ensure the quality of the testing procedure and reagents.  QC procedures for
susceptibility check organism dilution, plating technique, and the ability of the test
medium to obtain acceptable results.  If results of QC are not as expected, tests of
control strain(s) and isolates must be repeated.  The incubation temperature should
be monitored and  kept at 35-36 C.  o
59. Does your Mycobacteriology Laboratory examine broth cultures for evidence
of growth every 2-3 days for weeks 1-3, and weekly thereafter for a total of 6-8
weeks?
Rapid detection of M. tuberculosis is critical to diagnosing pulmonary tuberculosis
and to the detecting of drug-resistance.  BACTEC is more useful for the earlier 
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detection of M. tuberculosis than other systems currently available.  Average
detection time for mycobacteria is approximately 8-12 days, followed by an
additional 4-5 days for identification of M. tuberculosis complex.  The culture
positivity rate in this broth medium is higher than it is on conventional solid medium.
Read the inoculated BACTEC culture vials on the BACTEC instrument every 3-4
days for the first 2-3 weeks and once a week thereafter for a total of 6-8 weeks.
(Laboratories with small numbers of specimens may be able to read cultures three
times a week for the first 3 weeks of incubation and weekly thereafter for a total of
8 weeks.) 
BACTEC 12B vials that develop a GI of 25-50 and seem to stop growing may be
transferred to a fresh 12B vial, as this sometimes stimulates growth.  Smear
positive specimens that fail to grow in 6 weeks should be held for 8 weeks.
60. Does your Mycobacteriology Laboratory examine cultures on solid media for
evidence of growth twice weekly for 1-4 weeks, and weekly thereafter for a
total of 8 weeks?  
Standard practice requires frequent examination of cultures inoculated from the
original specimen onto solid media.  Rapid growers appear early during the
examination and can be transferred or referred for identification.  All cultures on
solid medium should be held for at least 8 weeks, but if the original smear was
positive and the cultures are negative at 8 weeks, further incubation is indicated.
Careful scrutiny using an inverted or dissecting microscope or hand lens is helpful
for early observation of typical colonies of mycobacteria and facilitates early
identification of M. tuberculosis complex using rapid methods.
61. Does your Mycobacteriology Laboratory use a microscope or hand lens to
examine agar plates and/or tubes for earlier visualization of mycobacterial
growth?
The liquid broth method is not available to all laboratories at this time, because of
limitations imposed by the lack of availability of instrumentation  and the need for
justification for capital investment.  Techniques to facilitate a more rapid diagnosis
of tuberculosis should be considered. Good results in isolating mycobacteria from
clinical specimens have been achieved using Middlebrook 7H10 and/or 7H11 agar
with microscopic examination.
Colonial morphology directs the selection of the specific nucleic acid probe for rapid
culture confirmation of M. tuberculosis.    
The dissecting microscope is a valuable aid in examining young colonies, in
determining the morphology of mature colonies, and in detecting the presence of
minute colonies of the more slowly growing species of Mycobacterium on plated
media.  A 3-10x hand lens is useful to examine tubed media.
Colony morphology is best observed on isolated colonies.  Colony variations on the
transparent 7H10 or 7H11 agar media may be observed with the aid of a dissecting
microscope.  Under magnification young, developing colonies appear as clusters
of bacilli that develop into typical colonies as they mature. Plates of a transparent,
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agar-based medium are inverted on the stage of a dissecting microscope. To
examine the colonies, use 10-60x magnification and transmitted light, with the
source below the stage so that it shines through the medium.
Welch et al.(42) used a brightfield or inverted microscope at 100-160x  to view the
microcolonies on solid media, examining the plates twice weekly for four weeks.
Stain the growth on culture plate or L-J tube with the Ziehl-Neelsen or Kinyoun's
stain to determine the acid-fastness and purity of the growth.  When in doubt about
growth rate, make a subculture on liquid or solid medium using  small inoculum and
note the time required for visible growth:  
! Rapid growers are fully matured within 7 days on subculture.
! Slow growers require more than 7 days.
Suspend growth in sterile buffer or bovine albumin for further testing, or submit on
L-J slant to reference laboratory for further study.  A preliminary report to the
physician will communicate the progress of the culture. 
62. Does your Mycobacteriology Laboratory perform an acid-fast smear from:
a. BACTEC vials exhibiting growth?
b. Selected colonies at an early stage of growth on solid medium?  
62a. Once the GI is 100 or more, prepare a smear and stain with an acid-fast stain and
examine the smear.  If contamination is detected, decontaminate the BACTEC vial
using one of the procedures for initial specimens and streak on a selective solid
medium or inoculate into a fresh BACTEC vial made selective by the addition of
antibiotics.  
Acid-fastness, cording and a slow growth rate in 12B medium are suggestive of M.
tuberculosis. A DNA probe may be used to confirm the identification of M.
tuberculosis complex or another species.
62b. Does your Mycobacteriology Laboratory perform an acid-fast smear from
selected colonies on solid medium at an early stage of growth? 
When visual examination of the growth on transparent agar or L-J medium reveals
suspicious colonies, prepare and stain smear(s), using an acid-fast stain.  Examine
the staining characteristics and note the cellular morphology.  Acid-fast staining
results and colonial morphology guides the laboratorian in subsequent steps for
confirmation and/or identification.  (All plates should be resealed before removal
from BSC.)  As with the selective broth, DNA probe may be used to confirm the
identification of M. tuberculosis complex on the surface of solid medium.
63. Does your Mycobacteriology Laboratory subculture all BACTEC vials
exhibiting acid-fast growth to solid medium? 
Inoculating Middlebrook 7H10 agar allows development of colonial morphology from
growth in the BACTEC vial.  Colonial types may be purified and further tested to
identify other mycobacteria that may be present.  A pure culture may be transferred
for stock cultures, reference, or quality control. Transferring to an L-J slant also
allows better discrimination of pigment for species identification.
Prepare and stain
acid-fast smears
from growth
positive BACTEC
vials and from
selected colonies
on solid media.
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*64. Does your Mycobacteriology Laboratory use a rapid method to presumptively
or specifically confirm the presence of M. tuberculosis complex:
a. From BACTEC vials?
b. from growth on solid media?
*64a. Once growth is detected in BACTEC broth, the organism can be specifically
identified by the High Pressure Liquid Chromatography (HPLC), AccuProbe nucleic
acid probe, (GenProbe, San Diego, CA) or presumptively identified as M.
tuberculosis complex by growth inhibition in the BACTEC NAP test.  Any acid-fast
isolate that is not identified at a Level II Laboratory must be sent to a Level III
Laboratory for identification. 
*64b. Does your Mycobacteriology Laboratory use a rapid method to presumptively
or specifically confirm M. tuberculosis complex from growth on solid media?
Colonial morphology and acid-fast smear result directs the selection of the specific
Accuprobe nucleic acid probe or other method for rapid culture confirmation of
organism from the M tuberculosis complex, allowing the species confirmation
within hours of detecting the colony.  The probe has excellent sensitivity and the
identification can be made within two hours from liquid or solid culture media. 
Level II and III laboratories should be prepared to use DNA probes for the
identification of M. tuberculosis complex.  Unusual or problem isolates should be
sent to state public health laboratories for resolution, including possible
consultation with CDC.  
The AccuProbe:
This is the only probe method currently available for identifying isolates of several
species of mycobacteria.  The system is based on the use of nucleic acid probes
that are complementary to species-specific rRNA.  Mycobacterial cells are lysed
by sonication, and exposed to DNA that has been labeled with a chemiluminescent
tag.  The labeled DNA probe combines with the organism's rRNA to form a stable
DNA:RNA hybrid.  A selection reagent hydrolyzes the signal on all unbound DNA.
Chemiluminescence produced by a DNA:RNA hybrid is measured in a
luminometer.  Nucleic acid probes provide the most rapid identification of
mycobacteria (25).
Any actively growing culture less than one month old recovered on any solid or
broth medium can be used with the AccuProbe. The accuracy of identification of
M. tuberculosis from an actively growing BACTEC vial with the AccuProbe is
nearly 100%.  Reportable results can be achieved within 2-4 hours, but up to 10 -5 
10 bacilli are required for reliable, reproducible results.  A known positive and6 _
negative control should be included with each batch of organisms tested to control
the performance of the equipment, the procedure, and the reagents. 
"Batching" of probe tests prolongs turnaround time of laboratory results.  To
respond to the increased incidence of tuberculosis, laboratories should commit to
doing probe tests more frequently to obtain results as quickly as possible.
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The M. tuberculosis complex probe does not differentiate between M. tuberculosis,
M. bovis, M. bovis (BCG), M. africanum, and M. microti.  The AccuProbe has
probes for the identifying M. tuberculosis complex, M. avium, M. intracellulare, M.
gordonae, M. avium complex, and M. kansasii (25).
The BACTEC NAP test:
The BACTEC NAP test utilizes D-nitro-"-acetylamino-$-hydroxypropiophenone
(NAP) to inhibit the growth of mycobacteria belonging to the M. tuberculosis
complex, while not inhibiting or only partially inhibiting the growth of mycobacteria
other than the M. tuberculosis complex.  Confirmation of the NAP test and further
identification require additional testing by conventional or other methods.  
Use an actively growing culture in an early growth phase of BACTEC 12B vial for
the NAP test. Growth from solid media can also be used for inoculum with the NAP
test (25).  
! Never report NAP test result if the growth index values in the control vial
increases slowly or not at all (25).
! Mixed cultures of two mycobacteria or contaminated cultures give erroneous
results. In such cases, an acid-fast stain helps to confirm a mixed culture or
culture contamination.  Examine the solid media cultures that were inoculated
simultaneously from the initial concentrated specimen for evidence of differing
colonial morphology and subculture to liquid media from the solid media.
! Tests should be performed at the temperature that provides the best growth
in the control. If poor growth in the control is observed, the possibility of
another optimum temperature should be investigated (33).
! Among mycobacteria other than M. tuberculosis complex, certain strains of
M. kansasii, M. gastri, M. szulgai, M. terrae, and M. triviale are partially
inhibited by the NAP test.  In such instances there is a longer lag phase in the
presence of NAP, and results interpreted in the first 2-4 days may be
misleading.  Incubate further and test for an additional 2-3 days before
reporting (25).
High Pressure Liquid Chromatography (HPLC):
HPLC has been used as a rapid method to detect mycobacteria and identify them
to the species level using standard chromatographic patterns.  A method using
HPLC analysis of the D-bromophenacyl esters of mycolic acids extracted from
saponified whole cells has demonstrated the distinctly different mycolic acid
patterns produced by different species (4).  The method is proving helpful,
especially in reference laboratories with many positive specimens of differing
species.  The initial cost of the equipment makes the method impractical for most
smaller laboratories.
65. Does your Mycobacteriology Laboratory telephone or fax a confirmed report
of M. tuberculosis to provider as soon as the results are available?
Verbally communicate to physician or provider any information that is crucial to
diagnosis and treatment:  morphology and pigmentation, results of the BACTEC
NAP test or AccuProbe test, presence of mixed cultures, isolation of M.
tuberculosis from multiple sites.  Report resistance to antituberculosis drugs as 
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soon as the results are known.  A verbal report should be documented and
followed by a written report on the same or the next day.  The final report should
include a record of the verbal and/or preliminary report.
*66. Does your Mycobacteriology Laboratory average 14-21 days between
receiving specimen and reporting M. tuberculosis complex on positive
specimens?
Reporting of M. tuberculosis complex should average 14-21 days from receipt
of specimen.
Primary culture in a selective broth (e.g., BACTEC 12B) medium (7-14 days),
confirmation of positive growth by AFB smear (2-4 hours), and confirmation by the
TB AccuProbe (2-4 hours) or the BACTEC NAP test (4-6 days) will permit a report
of M. tuberculosis complex within 14-21 days.
67. Does your Mycobacteriology Laboratory monitor the turnaround time of test
results to ensure that the majority of M. tuberculosis complex are identified
within 21 days of specimen receipt?
Management's decision to monitor, on a monthly or quarterly basis, the reporting
of M. tuberculosis test results represents a commitment to better patient care.  If
the laboratory program fails to meet a 21 day average turnaround standard for
identifying M. tuberculosis complex, management should focus on improving in this
area.
68. Does your Mycobacteriology Laboratory retain positive mycobacterial
cultures for one year?
Epidemiologic investigations often use strains of M. tuberculosis that were isolated
six to nine months previously.  Therefore, it is good practice to keep isolates for
at least one year.  Outbreak investigations entail defining and identifying common
patient exposures and the relatedness of M. tuberculosis isolates.  Fingerprinting
by the restriction fragment length polymorphism (RFLP) procedure is the most
accurate method to determine strain relatedness.
Many laboratories maintain a subculture of the first isolate in the refrigerator or
freezer that can be retested if the patient fails to respond to therapy.  The
laboratory can reexamine the initial isolate and a later one to determine if the
susceptibility pattern has changed during therapy.  
69. Does your Mycobacteriology Laboratory correlate the smear positive and
negative results with culture positive and negative results to evaluate
smear/culture quality?
Specimens that are smear positive are usually culture positive, unless the patient
is on therapy.  Smear positive, culture negative specimens occur rarely, generally
less than 2%.  The occurrence of excessive numbers of smear positive, culture
negative specimens suggests acid-fast contaminants in the system. Check tap and
distilled water first, then diluent, buffer, stain solutions, and other reagents
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(Attachment 9). The smear negative/culture positive specimen is usually
associated with the number of organisms present.  Cultures with >104
mycobacteria per milliliter of original specimen are usually smear positive.
70. Does your Mycobacteriology Laboratory document the percent of specimens
producing contaminating growth on culture media inoculated with
digested/decontaminated sediment as a way of monitoring the specimen
preparation process?
A contamination rate of 3-5% is considered acceptable in most laboratories
receiving fresh specimens.  If your laboratory is experiencing delays in delivery of
specimens, the contamination rate may be greater than 5%.  Although increasing
the concentration of NaOH will help reduce the contamination rate, it will also
increase the possibility of die-off of M. tuberculosis during the
digestion/concentration process.   
To further reduce contamination of cultures, make sure that specimens are
completely digested.  Partially digested specimens may not be completely
decontaminated.  Thoroughly mix contents of the centrifuge tube to assure that the
inside surface of the tube has been well decontaminated.  Increase the NALC
concentration to digest thick, mucoid specimens.  
If a contamination rate >5% persists, increase the amount of NaOH slightly.  With
the BACTEC system, consider increasing the amount of the PANTA supplement
only as a last resort, as increasing PANTA may inhibit slowly growing or fastidious
mycobacteria.
If your laboratory is experiencing little or no contamination, your decontamination
procedure may be too harsh.  The laboratory processing may kill too many
mycobacteria, diminishing the overall recovery rate.  An excellent discussion of
centrifugal efficiency and digestant toxicity may be found in the CDC Guide for
Level III Laboratories (24).
Monitor the contamination rate periodically as a quality control for the
decontamination process.  Record and maintain the value in your quality control
record.
71. Does your Mycobacteriology Laboratory subculture colonies with differing
morphology for use in species identification?
If more than one colony type is observed, select colonies of each type, and
prepare subcultures of each to establish purity of the cultures.  Send acid-fast
isolates to a Level III laboratory for identification if your laboratory cannot identify
species with certainty. 
72. Does your Mycobacteriology Laboratory compare the prevalence of M.
tuberculosis complex isolated in your laboratory to the prevalence in your
geographic area?
It is important to maintain records of the institutional findings compared with the
surrounding geographic area and region as a means to inform the physicians
and/or housestaff of local trends and findings.  Regional and state information is
available from the local or state TB Control or from CDC.
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73. Does your Mycobacteriology Laboratory perform susceptibility testing on all
initial isolates of M. tuberculosis?
The CDC recommends that initial isolates from all patients be tested for drug
susceptibility to confirm the anticipated effectiveness of chemotherapy. 
Susceptibility testing should be repeated if the patient continues to produce culture
positive sputum after 3 months of treatment. Monitoring drug resistance patterns
in specific locales can help to identify areas where infection control or public health
interventions may be necessary to prevent MDR-TB outbreaks.  
Local monitoring is also important for assessing the success of control programs
in areas that have already established the presence of drug resistance in isolates
(41).
74. Does your Mycobacteriology Laboratory determine the susceptibility of M.
tuberculosis to primary drugs using a liquid system such as BACTEC?
Second only to the need to know whether a patient is infected with M. tuberculosis,
is the need to know the most effective drug or chemotherapeutic agent(s) to use
to treat the patient. All primary isolates should be tested for susceptibility against
SIRE and pyrazinamide using the BACTEC method. This will provide the most
Inoculum for the BACTEC indirect drug susceptibility test may be prepared from
a positive 12B vial, from a solid agar medium, or from egg-based medium culture.
Confirmation procedures and susceptibility tests on acid-fast growth should be
carried out simultaneously to permit rapid identification of M. tuberculosis complex
and rapid reporting of results.  Drug susceptibility performed in BACTEC can be
reported within 4-5 days, and is often available by the time confirmation is
complete. Further susceptibility tests should be performed if resistance to one or
more of the primary drugs is suspected. Secondary drug testing is usually
performed in Level III laboratories having experience in M. tuberculosis
susceptibility testing using secondary drugs. 
Drug testing of M. tuberculosis isolates against additional antimicrobial agents can
be performed in many Level III laboratories using the same techniques as for
primary drugs. Second-line drugs and newer antituberculosis drugs being
developed for clinical use are being screened in the BACTEC system in some
larger Level III laboratories with results that correlate well with results in 7H10
agar. However, the experience of most laboratories with such testing is limited.
Drug susceptibility tests should be performed only in laboratories staffed by
personnel who are proficient in identifying the species of Mycobacterium being
tested and who perform a sufficient number of susceptibility tests to be aware of
the problems associated with the procedures.
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75. Does your Mycobacteriology Laboratory telephone, fax, or electronically
transmit a  drug susceptibility report to provider as soon as the results are
available and follow with a written report within 24 hours?
It is important to report drug susceptibility results to the attending physician or
health care provider as soon as the information is available.  An oral report of drug
susceptibility should be documented and followed by a written report on the same
or the next day.  The final report should include a record of the oral and/or
preliminary report.
If the patient has drug resistant tuberculosis, the information will be used by the
physician to modify or change patient chemotherapy, especially if the patient is not
improving on the assigned regimen. Many laboratories repeat "resistant" BACTEC
susceptibility results using conventional media, especially until experience using
the BACTEC system is gained. Correlation studies between the BACTEC system
and the conventional method are still being documented, and it is possible that the
recommended concentration of antimicrobials will be adjusted.
Send the comprehensive final report of preliminary information, final identification,
and drug susceptibility results to the clinician, the infection control officer, local or
state TB Control Division, and the medical records department.  Computerized
summary results may be sent to other laboratories, clinicians and public health
practitioners, as appropriate.
Since the drug susceptibility patterns are not always known at the time M.
tuberculosis is confirmed, information on drug resistance must be communicated
independently to the TB Control Program in the state where the patient resides.
This practice will ensure prompt and focused attention on the patient with drug
resistance and allow proper treatment, isolation and managed care for those with
treatment and/or compliance problems.  As regionalization of tuberculosis testing
occurs, this link between laboratory and local and state Public Health TB Control
Programs must be emphasized and secured.
*76. Does your Mycobacteriology Laboratory average 15-30 days between
receiving specimen and reporting primary drug susceptibility test results on
M. tuberculosis complex?
Laboratories must accept the responsibility of their role in the proper management
of patients infected with tuberculosis.  In the past, susceptibility testing has been
minimized, and reports have been sent whenever the identification/susceptibility
testing was complete.  Drug susceptibility testing has been handled almost as an
afterthought in too many institutions.  The importance of and attention to this
aspect of laboratory reporting have now become an essential link to patient
management. 
All Level II and Level III laboratories must focus on reducing turnaround time for
drug susceptibility testing to <30 days or consider referring all M. tuberculosis
cultures to a reference laboratory.
With attention focused on the necessity for rapidly reporting of susceptibility testing
results, the following approach should decrease turnaround time:
Susceptibility
results on M.
tuberculosis
should be
reported to
provider as soon
as available.
Report drug
susceptibility test
results to the
provider within
15-30 days of
specimen receipt.
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! BACTEC 12B vials with increasing growth index:  Perform indirect drug
testing using the five primary drugs at the same time the growth identification
procedure(s) is performed.
! Conventional method: Direct susceptibility testing on acid-fast smear positive
specimens produces results three to six weeks faster than indirect drug
testing.
! Level I Laboratories: Rapid transport and monitoring reference laboratory
results will help to reduce drug susceptibility turnaround time.
! Overnight mail to reference laboratory.
77. Does your Mycobacteriology Laboratory telephone, fax, or electronically
report result of confirmed positive M. tuberculosis complex and drug
resistant strains of M. tuberculosis complex to the Tuberculosis Control
Program in the state where the patient resides, as soon as the result are
available?
A real concern in the present environment of increasing numbers of tuberculosis
cases and drug resistance is the interstate reporting of tuberculosis cultures.
Commercial laboratories operating between states must be committed to
notifying the health officials in the state where the patient resides to ensure
that the link between diagnosis and investigation occurs. 
Disseminating information that is essential for public health investigations must be
faithfully and reliably initiated by all laboratories performing tuberculosis culture and
identification.  Appendix 10 lists the individual state requirements for reporting
patient information to the state health department (10). State requirements for
confinement, contact investigation, treatment, and follow-up must be met by the
State TB Control Program.
Detection of resistant strains of M. tuberculosis must be reported directly to the
physician or infection control staff, the local public health practitioners and the
state  TB Control Program.  The epidemiologic follow-up and control of both drug-
resistant and drug-susceptible tuberculosis depend on a cooperative approach that
begins with the laboratory notifying the local and state health department.
Duplicate notification is not a concern.
78. Does your Mycobacteriology Laboratory monitor the turnaround time for
reporting primary drug susceptibility test results on M. tuberculosis isolates
to ensure that reports are sent within 30 days of specimen receipt?
Management's decision to monitor the drug susceptibility testing on a monthly or
quarterly basis will be viewed as a commitment.  If the laboratory program fails to
meet the prescribed standard of practice, management should focus on improving
specific areas.  An average 30 day turnaround time for reporting primary drug
susceptibility results on M. tuberculosis is reasonable, and a longer average
turnaround time shows need for improvement.
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79. Does your Mycobacteriology Laboratory monitor the resistance patterns of
M. tuberculosis and make information available to house staff, local, and
State Tuberculosis Control Program?
The provider/physician has little opportunity to observe trends.  By monitoring drug
results in the laboratory, trends can be observed more quickly.  This information
will assist physicians in drug selection, permitting the medical community to deal
more effectively with new patients or patient contacts.  Implementing rapid
technology that will reduce the turnaround time for reporting the drug
susceptibilities of tuberculosis is critically needed to resolve the current MDR-TB
problem.
80. Does your Mycobacteriology Laboratory submit outbreak-associated strains
of M. tuberculosis through the state public health laboratory to a restriction
fragment length polymorphism (RFLP) reference laboratory for
fingerprinting?
Laboratories must be able to support outbreak investigations and special studies
of MDR-TB.  Isolates can be sent to regional laboratories performing a procedure
for fingerprinting, restriction fragment length polymorphism (RFLP).  Subtyping of
M. tuberculosis by RFLP is a powerful tool for tracking the spread of individual
strains and testing for laboratory cross-contamination when suspected.  
RFLP is a means of "fingerprinting" the DNA.  This DNA fingerprinting uses
repetitive sequences located on the chromosome to characterize each isolate of
M. tuberculosis.  RFLP typing does not have the disadvantage of plasmid profile
analysis which uses extra-chromosomal genetic material that can readily be lost
(30).  RFLP has been used to:
! Study nosocomial transmission of MDR-TB among patients with HIV
infections.
! Confirm reinfection in AIDS patients with a second strain of M. tuberculosis.
! Identify unrecognized sources of transmission through population surveys.
! Identify laboratory cross-contamination.
! Trace hospital or nursing home acquired tuberculosis.
! Determine strain relatedness of tuberculosis within a community.
! Establish a background of prevalent strains within a community against which
an outbreak or drug resistant pattern can be compared.
Eight strategically located regional centers for RFLP studies (Appendix 6) have
been established in Level III laboratories across the United States with
coordination through the state public health laboratory system.  Level II and Level
III laboratories may avail themselves of this service by contacting the state
laboratory director in the patient's state of residence (Appendix 6).  
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LEVEL III LABORATORIES ANSWER QUESTIONS 
1-39; 42-84
81. Does your Mycobacteriology Laboratory identify a broad range of
mycobacterial species?
Laboratories qualifying as Level III laboratories must work to develop and enhance
their reference capability:
! Utilize currently available laboratories resources for providing services to meet
patient needs according to risk/disease prevalence.  Standardize electronic
transfer of information through software to avoid duplication of effort.
! Recognize and standardize key elements to link testing laboratories and
community users of results with CDC.
! Coordinate timely transfer of critical test results with those providers and
agencies that need to know.
82. Does your Mycobacteriology Laboratory perform drug  susceptibility studies
against other mycobacteria in addition to M. tuberculosis?
Reference laboratories may or may not perform drug testing on mycobacteria other
than M. tuberculosis (MOTT) bacilli.  Although the modified proportion method has
been used for testing most species of slowly growing mycobacteria, no method is
yet accepted for susceptibility testing of mycobacteria other than tubercle (MOTT)
bacilli.  The difference in the susceptibility pattern of MOTT bacilli provided by
BACTEC and conventional methods is being  investigated.  The clinical relevance
of the in-vitro susceptibility test results obtained for MOTT bacilli has not been
determined.  Tests should be conducted in large or reference-type laboratories
with sufficient competence to be aware of the limitations of current practices.
CDC reported in January , 1992 that most M. avium complex (M. avium or M.
intracellulare) isolates are resistant to all of the antituberculosis drugs routinely
tested, and there are no convincing published data that demonstrates therapeutic
success with these drugs even when in vitro tests indicate susceptibility to a
specific drug.  It therefore serves no useful purpose to pursue susceptibilities
against M. avium complex.  CDC does not routinely accept reference strains of M.
avium complex for susceptibility testing.
With the exception of M. smegmatis, which is susceptible to ethambutol, the
pathogenic, rapidly growing mycobacteria are resistant to achievable serum and
tissue levels of all first-line anti-tuberculosis drugs.  Neither the broth microdilution,
agar disk-elution, nor the disk-diffusion method has been approved by the  National
Committee for Clinical Laboratory Standards (NCCLS) for testing of the rapidly
growing mycobacteria (22).
83. Does your Mycobacteriology Laboratory use one of the following rapid
methods to identify mycobacteria:
a. DNA probe?
b. High performance liquid chromatography (HPLC)?
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83a. AccuProbe, a  DNA probe currently available for identifying cultures of M.
tuberculosis complex, has excellent sensitivity.  Identification can be accomplished
within 2 hours on growth from liquid or solid culture (41). Level II and III
laboratories isolating mycobacteria should be prepared to use DNA probes for
identifying M. tuberculosis complex (30). An organism with colonial morphology on
solid media consistent with strains of the M. tuberculosis complex, or an organism
growing in liquid medium and suspected of being M. tuberculosis  should be
tested. Testing with nucleic acid probes should be combined with isolation of
mycobacteria in liquid culture. Liquid cultures positive for M. tuberculosis nucleic
acid can be subcultured to a solid medium to rule out mixed mycobacterial
cultures. The growth of the subculture on Middlebrook 7H10 or 7H11S can also be
used later for  biochemical tests, susceptibility testing, and for stock culture(s).
Manufacturers are being encouraged to develop a rapid, amplified testing system
to provide direct identification of M. tuberculosis from the patients' specimens and
a stand-alone screening test for other mycobacterial pathogens (30).
Nucleic acid probes are also available for the culture identification of M. avium
complex, M. avium, M. intracelllulare, M. gordonae and M. kansasii.
.
83b. Does your Mycobacteriology Laboratory use high performance liquid
chromatography (HPLC) to identify mycobacteria?
HPLC applications for the identification of mycobacteria have been available to the
clinical laboratory since the late 1980's.  Extraction and derivatization of mycolic
acids from the cell wall of mycobacteria and subsequent chromatographic analysis
yield distinctive peaks which are identified by computer-assisted pattern
recognition programs.  This method identifies a wide range of mycobacterial
species, the test takes less than 2 hours, and the procedure can  be combined
with BACTEC to offer a rapid detection/identification scheme.  It is recommended
that larger Level III laboratories adopt this rapid technology for routine use (30).
Although gas liquid chromatography (GLC)  has been used in the past for analysis
of the mycolic acid in mycobacteria, at least one study has found that GLC alone
is insufficient to accurately identify mycobacteria (41).  The GLC method is not as
widely used for mycobacteriology applications as AccuProbe and HPLC.
84. Does your Mycobacteriology Laboratory not report the identification of M.
tuberculosis  based solely on polymerase chain reaction (PCR) results?
Although PCR holds great promise for the future, researchers have concerns with laboratories must
nucleic amplification methods that must be addressed before widespread use can
be recommended.  Concurrent microbiological procedures for the isolation of M.
tuberculosis are now and probably always will be appropriate for quality control of
amplification techniques.  The laboratory community is awaiting Food and Drug
Administration (FDA) approval to assure that sufficient data exists on the false
positive and false negative rates, predictive values, and reproducibility of PCR test
results.  Mycobacteriology laboratories must continue to rely on established
techniques until the FDA approves amplification technologies (30).  
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ASTPHLD
The Association of State and Territorial Public Health Laboratory Directors (ASTPHLD) represents the state
public health laboratory directors throughout the United States and its territories.
ASTPHLD maintains a Washington, D.C. headquarters office and seven Area Resource Offices of the
National Laboratory Training Network (NLTN).  NLTN is a cooperative training system sponsored in
conjunction with the Centers for Disease Control and Prevention (CDC) that forms alliances among federal,
state and local health agencies and private sector organizations to develop and deliver localized laboratory
training programs based on documented need.  ASTPHLD organizes and presents scientific conferences and
symposia relevant to testing activities of public health laboratories.  This project was co-sponsored as a joint
activity of the ASTPHLD and the CDC.
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MYCOBACTERIA AUDIOVISUAL RESOURCES AVAILABLE
IN THE NLTN AREA RESOURCE OFFICES
Note: Some offices may have additional resources; please contact the NLTN office serving your
area for specific resource information.
MANUALS
"Laboratory Manual for Acid-Fast Microscopy", 2nd Ed.  (CDC '76)
"Isolation and Identification of Mycobacterium Tuberculosis:  A Guide for the Level II Laboratory"
(CDC)
"Public Health Mycobacteriology:  A Guide for the Level III Laboratory" (CDC:1985)
VIDEOTAPES OF LABORATORY PROCEDURES
"Safety in the Mycobacteriology Laboratory" (CDC: 1982: 18 min)
"In Case of Accident...Control of Airborne Mycobacteria" (CDC: 1981: 17 min)
"Primary Isolation of Mycobacteria Using the N-Acetyl-L-Cysteine-Sodium Hydroxide Method" (CDC:
1980: 12 min)
Biochemical Identification of Mycobacteria I  (CDC: 1980)
# "3-day Arylsulfatase Test for Mycobacteria" (6 min)
# "3-day Tellurite Reduction Test for Mycobacteria" (6 min)
# "Sodium Chloride Tolerance Test for Mycobacteria" (6 min)
"Acid Fast Microscopy" (CDC: 24 min)
"Specific Identification of Mycobacterium tuberculosis" (CDC: 12 min)
"Rough Grouping of Mycobacteria" (CDC: 15 min)
"Drug Susceptibility Testing of Mycobacterium tuberculosis" (CDC: 27 min)
Biochemical Identification of Mycobacteria II  (CDC: 1985/86)
# "Urease Test for Mycobacteria" (10 min)
# "Iron Uptake Test for Mycobacteria" (10 min)
# "MacConkey Agar Test for Mycobacteria" (10 min)
# "Tween Hydrolysis Test for Mycobacteria" (9 min)
"Meeting the Challenge of Multi-Drug-Resistant TB:  The Laboratory DOES Make a Difference" (CDC:
1992 : 18 minutes)
"Isolation and Identification of Mycobacterium Tuberculosis Module VI:  Acid-Fast Microscopy in
Mycobacteriology"
Appendix 6.3
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"A New Era in Mycobacteriology:  Identification by High Performance Liquid Chromatography"
(Waters:  1994)
Appendix 6.3
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"TB The New Epidemic" (Fulton, Comie, Canfield, Inc.)
"Isolation and Identification of Mycobacterium Tuberculosis Module V:  Isolation of Mycobacteria
Using N-Acetyl-L-Cysteine-NaOH for Digestion and Decontamination" (CDC: 1980:  10 min)
"Isolation and Identification of Mycobacterium Tuberculosis Module VII:  Identification of M.
tuberculosis" (CDC: 1985: 28 min)
"Preventing Tuberculosis in Children:  We All Can Help" (Duke & Associates: 1994: 12 min)
"Tuberculin Skin Testing" - Mantoux (CDC: 20 min)
TRAINING COURSE PACKAGES
Isolation and Identification of Mycobacterium tuberculosis:  A Workshop for the Level II Laboratory
(CDC:  1991)
Manual (Vol. I)
Slide Set (Vol. II)
Editor:  Billie Ruth Bird
Original Authors: Patricia T. Kent, B.S., George P. Kubica, Ph.D. (Now Retired)
This 2½ day wet workshop is designed to provide essential information and laboratory
experience for training personnel in a Level II mycobacteriology laboratory in:  microscopic
identification of AFB, culture of clinical specimens, identification and drug susceptibility testing
of M. tuberculosis isolates.  Both classic and rapid diagnostic methods are presented.
Note: Includes 2 volumes (printed materials and kodachrome slides) and 4 videotapes, "Isolation
of Mycobacteria Using N-Acetyl-L-Cysteine-NaOH for Digestion and Decontamination," "Acid Fast
Microscopy in Mycobacteriology," "Identification of M. tuberculosis," "Drug Susceptibility Testing of
M. tuberculosis."
Multidrug-Resistant Tuberculosis:  The Laboratory Does Make a Difference (CDC: 1992)
Authors: Billie Ruth Bird, Jack T. Crawford, Ph.D., Bess Miller, M.D.
This half-day seminar dials with the critical issue of multidrug-resistant tuberculosis (MDRTB)
by focusing on the need for laboratories to reduce turnaround time for testing and reporting
tuberculosis.  Information is provided on currently available laboratory strategies that can
reduce the time for TB testing and reporting.  Problem solving exercises and interactive class
discussions provide examples and suggestions on ways to use the strategies.
Appendix 11: Reference Laboratory Scores on Self-Evaluation
REFERENCE LABORATORY SCORES ON SELF-EVALUATION
As part of the pilot testing of this document, nine Level III laboratories were identified by the Technical
Advisory Committee as well-established reference laboratories with excellent reputations in diagnostic
mycobacteriology.  No laboratories of committee members were included in the nine.  Personnel in
these nine Level III laboratories were asked to evaluate their laboratories using this document.  They
were asked to share their scores so that future users of this assessment tool would have a reference
for comparison.
Results from the nine reference laboratories are presented in the chart below.  Expressed in percent
are the Mean or average scores and the range of scores.  The highest percent (High) scored by a
laboratory and the lowest percent (Low) scored are given below for each category.  
To compare your laboratory to the experts, determine your scores (express them in percent) for each
category and for the overall total.  Enter your scores into the chart rows below marked Your
Laboratory's Scores.  Compare your scores to those of the experts.  If your scores fall within the
experts' range, you can infer that your overall laboratory practices are equivalent to  the practices of
some of the best mycobacteriology laboratories in the United States.  If your scores are below the
experts, this indicates the need to review your practices and institute changes.
Self-assessment questions written in red are critical issues and the results to these questions should
be evaluated separately.  A "no" to any of these question indicates a need for improving practices in
that area.
PERCENT SCORES FROM REFERENCE LABORATORIES
Coll/Han Safety Lab Prac QA/QC CDC Rec Overall
High 96.7% 100% 96.1% 98.3% 95.6% 95.4%
Low 71.7% 88.2% 78.6% 81.2% 81.5% 82.9%
Mean 90.8% 94.4% 88.6% 89.9% 89.8% 90.0%
Your Laboratory’s Score
Date Coll/Han Safety Lab Prac QA/QC CDC Rec Overall
